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 The term “natural product” refers to secondary metabolites produced by living 
organisms, and therefore encompasses a number of research concentrations ranging from 
traditional medicines to microbial lead compounds to the impacts of diet on human 
health. The projects described here involve several diverse investigations that cover some 
of the great breadth of natural products research. One project examined the drug-diet 
interaction between grapefruit constituents and first-pass metabolism enzymes, including 
cytochrome P450s and organic anion transporter proteins. The bioactive components of 
grapefruit juices and dietary supplements, including several furanocoumarins and 
flavonoids, were quantified. A contrasting project, related to drug discovery through the 
screening of fungi, explores a different facet of natural products research. The impact of 
media modification on the production of fungal secondary metabolites was examined, 
using known metabolites to track production potential of various culture media. In 
addition, a chemical epigenetics approach was used to induce new secondary metabolites 
by causing the transcription of normally silent fungal genes. Finally, a review article 
explored the history of a microbial metabolite that made it through the drug development 
process to become an anti-cancer treatment. 
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CHAPTER I 
COMPOUNDS LEADING TO DIET-DRUG INTERACTION 
History of the “Grapefruit Juice Effect” 
There is a common misconception that because something is natural, it is safe. 
While the fallacy of this notion is easily disproved (pathogens, for example, are both 
natural and quite harmful), consumer products are increasingly labeled “all-natural.” This 
trend could potentially lead to consequences, as most people do not expect or even 
suspect the food or supplements they ingest to interfere with their medication.  
In the last several decades, grapefruit has made such interactions more widely 
known. Its effect was first discovered serendipitously, during a 1989 clinical trial 
examining potential interactions between alcohol and felodipine, an antihypertensive 
drug.1 Grapefruit juice was used as a matrix to mask the flavor of the ethanol. 
Unexpectedly, plasma concentrations of the felodipine were three and five times what 
was expected in all patients, not just those consuming alcohol. The authors of the paper 
postulated that the grapefruit juice matrix was the cause, and confirmed this in a 
subsequent paper two years later.2  
The primary mechanism for this interaction was shown in 1998 to be the 
irreversible inhibition of cytochrome P450s (CYPs).3 The CYP enzymes are major 
mediators of first-pass metabolism, and their inhibition can result in various side effects, 
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ranging from headaches to kidney toxicity.4-7 The class of compounds in grapefruit 
responsible for this inhibition was identified as furanocoumarins, most notably 
bergamottin and 6´,7´-dihydroxybergamottin (DHB; Fig. 1).4  
 
Figure 1. Bergamottin (1) and 6′, 7′-dihydroxybergamottin (DHB; 2) 
Interactions with Cytochrome P450 Enzymes 
The CYP enzymes have been reported to account for almost half of the overall 
elimination of commonly prescribed drugs,8 though its isoforms are involved in the 
metabolism of many more. The CYP3A isoforms alone, including both CYP3A4 and 
CYP3A5, are involved in the metabolism of over half of common medications, making 
the CYP3As arguably the most important family.6  
Furanocoumarins have been shown to inhibit multiple isoforms in vitro, including 
subfamilies from the CYP1, CYP2, and CYP3 families. The in vitro inhibition of the 
CYP3A4s by furanocoumarins varies by compound; the potency of DHB, for example, is 
greater than that of bergamottin and bergaptol but less than the paradisins (dimers of 
DHB).9, 10 A study using paradisin C, DHB, bergamottin, and bergaptol determined IC50 
values of 0.09, 0.42, 10, and 69 µM, respectively.6 In addition to differing IC50 and Ki 
values,11 DHB and bergamottin differ in their time courses for CYP3A4 inhibition; while 
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maximal inhibition by DHB was achieved within 30 min, up to 3 h was required for 
bergamottin to significantly reduce CYP3A4 activity.12 Such in vitro studies suggest that 
the importance of DHB in potential drug-diet interactions far outweighs that of 
bergamottin. This is corroborated by studies demonstrating no clinically significant 
inhibition by two beverages known to contain high levels of bergamottin, but no DHB.13, 
14 Pure bergamottin in doses up to 12 mg also failed to increase mean felodipine AUC.15 
Similar studies for the paradisins are not available.  
CYP3A inhibition by the furanocoumarins is primarily mechanism-based; i.e., the 
compounds bind irreversibly to the enzyme, precipitating a loss of the enteric CYP3A 
proteins without affecting CYP3A mRNA.16 The consequence of this fact is that prior 
exposure to grapefruit juice is sufficient to produce a reaction; grapefruit, or its active 
components, do not need to be consumed concurrently with medication to induce a 
reaction.17 Recovery of CYP3A activity requires the production of new enzymes, a 
process with a half-life of approximately 24 h.18  
 
Interactions with P-glycoprotein 
P-glycoprotein (P-gp) is a transmembrane protein localized to the apical 
membrane of hepatocytes and enterocytes. It acts to decrease absorption of medications 
by transporting drugs into the bile and intestinal lumen. Its substrate specificity overlaps 
widely with CYP3A,19 and its potential role in augmenting the increase in drug exposure 
by CYP3A inhibitors has been investigated. Grapefruit juice, as well as the 
furanocoumarins Paradisin A, bergamottin, DHB, bergapten, and bergaptol have 
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demonstrated P-gp inhibition in vitro.9, 20 Despite these in vitro studies, there is little 
evidence grapefruit juice has more than a minimal effect on P-gp activity.6, 21-23 
 
Interactions with Organic Anion Transporter Proteins 
Complicating the drug metabolism story are the organic anion transporter proteins 
(OATPs), found throughout the body, including enterocytes. The OATPs are involved in 
drug uptake, and their inhibition can decrease AUC. Furanocoumarins are OATP 
inhibitors, but in vitro and in vivo data indicate that flavonoids are primarily responsible 
for OATP inhibition by grapefruit juice.24-27 This effect varies depending on which probe 
substrate is used. Unlike CYP3A inhibition, OATP inhibition by grapefruit components 
is brief, lasting less than 4 h.28  
Similar to P-gp, many drugs are substrates for both CYP3A and OATP, and 
OATPs may therefore play a minimal role in drug exposure in the context of grapefruit 
inhibition.29 However, the overlapping substrate specificity of these enzymes also 
suggests that the most accurate way to analyze the impact of grapefruit juice and its 
components on a drug’s metabolism is to perform clinical pharmacokinetic studies.6 
 
Aims of this project 
Furanocoumarins and flavonoids, while natural compounds, have the potential to 
cause severe side effects when consumed with medications that undergo metabolism by 
cytochrome P450s. Grapefruit juice, as well as botanical supplements that contain 
grapefruit or its active components, pose a risk to uninformed consumers. To assess this 
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risk, several grapefruit juices and nutritional supplements were analyzed. In concert with 
clinical studies that examined the biological impact of the juices and supplements, a 
quantitative chemical analysis was performed to gain an understanding of the expected 
concentrations of potentially harmful natural products. 
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CHAPTER II 
RAPID QUANTITATION OF FURANOCOUMARINS AND FLAVONOIDS IN 
GRAPEFRUIT JUICE USING ULTRA PERFORMANCE LIQUID 
CHROMATOGRAPHY 
 
     This chapter has been published in the journal Phytochemical Analysis and is      
     presented in that style. VanderMolen, K.M., Cech, N.B., Paine, M.F., Oberlies, N.H.  
     Phytochem. Anal. 2013. 24, 654-660. 
 
Introduction 
Grapefruit juice has been shown to increase the systemic exposure of a diverse 
array of oral medications that undergo extensive pre-systemic metabolism by cytochrome 
P450 3A (CYP3A) in the intestine, including felodipine, lovastatin, and cyclosporine.4-7 
The increase in systemic drug exposure can be sufficient to cause untoward effects, 
ranging from relatively mild (e.g., hypotension and dizziness with some calcium channel 
blockers) to potentially severe (e.g., nephrotoxicity with some immunosuppressants). The 
mechanism underlying these interactions is irreversible inhibition of intestinal CYP3A 
activity by grapefruit juice.3, 4, 6, 21 Furanocoumarins, a class of compounds present in 
grapefruit juice, have been established as major CYP3A inhibitors in human volunteers.4 
This effect may be augmented if the “victim” drug also is a substrate for P-
glycoprotein(P-gp), a transmembrane efflux transport protein located on the apical 
membranes of numerous cell types, including enterocytes.6, 21 P-gp demonstrates 
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substrate specificity that overlaps with that of CYP3A substrates,19 and several in-vivo 
and in-vitro studies have shown an inhibitory effect by grapefruit juice and/or 
furanocoumarins towards P-gp activity.30-35 A more recently discovered mechanism 
underlying grapefruit juice-drug interactions is inhibition of intestinal organic anion 
transporting polypeptides (OATPs), which are uptake transporters located on the apical 
membranes of enterocytes and other cell types.7, 36 Opposite to P-gp, OATPs in the 
intestine act to facilitate drug absorption. Thus, inhibition of these transport proteins leads 
to a decrease in systemic exposure of drug substrates, including the antihistamine 
fexofenadine36, 37 and the antihypertensive agent aliskiren,38, 39 with the consequent 
potential for therapeutic failure. Candidate OATP inhibitors in grapefruit juice include 
the flavonoids naringin and hesperidin.40 The potential for drug interactions with a widely 
available food product necessitates an understanding of the expected concentrations of a 
suite of structurally diverse and potentially bioactive compounds.  
Reported analytical methods for measuring furanocoumarins in fruit juices 
typically require separation times of one hour or more.38, 39, 41-44 For example, in 2005, a 
study of the distribution of furanocoumarins in grapefruit juice fractions utilized a 65-min 
high performance liquid chromatography (HPLC) method.44 The same year, an 
exhaustive analysis of several furanocoumarins and furanocoumarin dimers in 58 juices 
employed a similar 65-min method.45 The following year, a 45-min HPLC method was 
utilized to determine the concentrations of bergamottin and 6′,7′-dihydroxybergamottin in 
grapefruit juice.43 In 2009, a shorter HPLC method was developed for the determination 
of five furanocoumarins (bergaptol, psoralen, bergapten, bergamottin, and 6′,7′-
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dihydroxybergamottin) in citrus juices that required a run time of 23 min, which appears 
to be the most rapid method published to date.46 As with the furanocoumarins, analytical 
procedures for measuring flavonoids often employ methods of one hour or more. A 
survey of 9 commercial grapefruit juices and associated flavonoid concentrations 
published in 2000 utilized a 60 min method.41 Six years later, a 65 min method in a 
similar survey of orange and grapefruit juices was published,39 followed the next year by 
another 60 min method for the simultaneous analysis of adrenergic amines and flavonoids 
in fruit jams and juices.38 De Castro et al. utilized a 70 min separation to determine the 
concentrations of naringin and naringenin.43 The most rapid HPLC analyses of flavonoids 
reported in the literature was a 45 min method published in 2008.47 A handful of UPLC 
analyses of flavonoids in food, supplements and traditional Chinese medicines have 
appeared in the literature in the last few years as well. The majority of these studies48-51 
utilize a C18 column and UV detection, though one expansive study quantifying 39 
phenolic compounds in apples52 additionally used electrospray ionization mass 
spectrometry (ESI-MS) to confirm the identity of the analytes. The most rapid of these 
UPLC studies quantified 11 flavonoids (including those listed in this paper) in three 
citrus fruit extracts, and had a run time of 5.5 min.50 
Ultra performance liquid chromatography (UPLC) offers significant advantages in 
sensitivity and speed compared to conventional high performance liquid chromatography 
(HPLC). After overcoming the difficulties presented by working with very high 
pressures,53-55 early studies demonstrated enhanced resolution and sensitivity, reduced 
solvent consumption, and rapid analyses56-58 with UPLC compared to that which can be 
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achieved with HPLC. With greater integration in diverse research areas, UPLC offers the 
opportunity to streamline quantitative determinations, such as those described herein, 
reducing cost and expediting research.  
The goal of this study was to develop rapid (< 5.0 min) methods for the 
quantitation of two furanocoumarins (bergamottin and 6′,7′-dihydroxybergamottin) and 
four flavonoids (naringin, naringenin, narirutin, and hesperidin) in grapefruit juice using 
UPLC (Fig. 2). An additional goal was to apply these methods to determine the 
concentrations of the aforementioned analytes in five grapefruit juices used in previous 
clinical interaction studies. 
 
Experimental  
Instrumentation 
UPLC analyses were performed using a Waters Acquity UPLC system (Milford, 
MA) equipped with an autosampler, photodiode array detector (PDA), column manager, 
and binary solvent manager.  Data were collected and analyzed using Empower software. 
An HSS C18 column (50 mm × 2.1 mm i.d., 1.8 µm, Waters, Milford, MA) was used for 
all chromatographic analyses.  
 
Materials 
Bergamottin (purity ≥ 96.9%) was purchased from ChromaDex (Irvine, CA, 
USA); narirutin (purity ≥ 99.0%) was purchased from Indofine (Hillsborough, NJ, USA); 
naringin (purity ≥ 96.8%), naringenin (purity ≥ 99.9%), hesperidin (purity ≥ 97.0%), and 
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6′,7′-dihydroxybegamottin (purity ≥ 97.2%) were purchased from Sigma-Aldrich (St. 
Louis, MO, USA). Purity of standards are reported as determined by HPLC by the 
manufacturers. Methanol, ethyl acetate, and acetonitrile were purchased from Pharmco-
Aaper (Shelbyville, KY, USA). 
 
 
 
Figure 2. Structures of the furanocoumarins bergamottin (1) and 6′,7′-dihydroxybergamottin (2) 
and the flavonoids naringin (3), narirutin (4), naringenin (5), and hesperidin (6). 
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Juices A and B were used in clinical studies with felodipine,4 cyclosporine,35 and 
fexofenadine.59 Juice A was a commercially available product. Juice B was the same 
juice, but the furanocoumarin fractions were removed using a series of food-grade 
solvents and absorption resins and column chromatography.4 Juice C was a commercially 
available concentrated grapefruit juice (Minute Maid Premium 100% Pure Frozen 
Concentrated Grapefruit Juice with added calcium). A dilution of Juice C was used in a 
clinical study examining the effect of grapefruit juice on the systemic exposure of 
loperamide and the CYP3A-mediated metabolite, desmethylloperamide.60 Juice D 
(Florida’s Natural Original Ruby Red 100% Pure Florida Grapefruit Juice) and Juice E 
(Simply Orange Juice Co. Simply Grapefruit 100% Pure Squeezed Grapefruit Juice) were 
commercially available not-from-concentrate juices and were purchased from a local 
grocery store. 
 
Standards preparation 
Bergamottin and 6′,7′-dihydroxybergamottin were dissolved in methanol to 
produce a 1.03 mM (bergamottin) and 1.00 mM (6′,7′-dihydroxybergamottin) multi-
standard stock solution. This solution was used to prepare seven standard solutions at 
concentrations ranging from 10.3 to 659 μM (bergamottin) and from 10.0 to 640 µM 
(6′,7′-dihydroxybergamottin). Naringin, narirutin, naringenin, and hesperidin were 
dissolved separately in methanol to produce stock solutions of 10.0 mM, 7.92 mM, 10.2 
mM, and 9.97 mM, respectively. These stock solutions were used to prepare standard 
solutions for each compound (six for naringin, five for each of the other flavonoids) at 
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concentrations ranging from 0.649 to 5.00 mM (naringin), 0.198 to 3.17 mM (narirutin), 
3.18 to 814 µM (naringenin), and 3.12 to 798 µM (hesperidin). 
 
Sample preparation 
Juice extracts were prepared by transferring 25.0 mL of each juice to a 50-mL 
conical polypropylene tube. After adding 20.0 mL of ethyl acetate, the contents were 
shaken vigorously and centrifuged (2500 × g for 30 min at 25 °C). The resulting organic 
layer was transferred by Pasteur pipette to a 250 mL round-bottom flask. An additional 
20.0 mL of ethyl acetate were added to the remaining contents of the tube, shaken and 
centrifuged, and the resultant organic layer was combined with the first organic layer. 
This extraction procedure was repeated a third time, and the combined organic layers 
were evaporated in vacuo. The residue in the round-bottom flask was transferred 
quantitatively to a 2 mL vial, using methanol as a rinse, and evaporated to dryness under 
air. This material was resuspended with 5.00 mL of methanol, yielding a 5-fold 
concentrated extract of each juice.  
 
Chromatographic conditions 
Quantitative analysis of furanocoumarins (bergamottin and 6′,7′-
dihydroxybergamottin). A 6 µL volume of each 5-fold concentrated juice extract was 
injected and analyzed at a wavelength of 250 nm. Chromatographic separations were 
carried out with a mobile phase consisting of HPLC-grade acetonitrile (solvent A) and 
nanopure water (solvent B) at a flow rate of 0.6 mL/min.  The following linear gradient 
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was used: 0.0 min, 30% A; 4.0 min, 100% A; 4.5 min, 100% A.  The column temperature 
was 30 °C.  
 
Quantitative analysis of flavonoids (naringin, narirutin, naringenin, and 
hesperidin).  A 6 µL volume of each 5-fold concentrated juice extract was injected and 
analyzed at a wavelength of 310 nm. The following linear gradient was used: 0.0 min, 
10% A; 1.0 min, 20% A; 2.0 min, 20% A; 2.5 min, 40% A; 3.5 min, 100% A; 4.0 min, 
100% A. Solvents A and B, the flow rate, and column temperature were the same as 
described in the previous section. 
 
Method Validation 
The identities of analyte peaks in the juice extracts were confirmed by comparing 
the UV spectra of the peaks and their standards, as well as, in the case of the flavonoids, 
by co-injection of the standards with the juices (Appendix, Figures S1 and S2).   
Linearity of the calibration curves was assessed by least-squares analysis. 
Precision and accuracy were determined by calculating the relative standard deviation 
(RSD) and relative error (RE), defined as the percent difference between the mean 
observed concentration and the nominal concentration, of three replicate analyses of the 
standards. All analyses were performed in triplicate in a single day. Interday RSD and RE 
were determined by analyzing the standard solutions in triplicate on three separate days. 
The limit of detection (LOD) was defined as the concentration corresponding to the 
signal detection limit, which was defined as b + 3sy, where b is the y-intercept of the 
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calibration curve, and sy is the standard deviation of the vertical deviations.61 The limit of 
quantitation (LOQ) was defined as b + 10sy.  
 
Results and Discussion 
Method Validation 
All standard curves exhibited coefficients of determination (r2) greater than 0.999 
(Table 1). Baseline resolution of all analytes (Fig. 3), both as standards and in the juice 
extracts, was achieved (Figs. 3 and 4). Precision and accuracy data are summarized in 
Table 2. RSD of the furanocoumarin standards (1 and 2) was below 0.33% (intraday) and 
3.1 % (interday) for all standard concentrations. The intraday RSD values of analytes 3, 
4, and 5 were below 1.5%, 2.6%, and 2.9%, respectively, while the interday RSD 
averages for each analyte remained below 1.0%. For analyte 6, the largest RSD value was 
4.7% at the lowest concentration of that standard, while the interday RSD was 3.1%. For 
the furanocoumarins (1 and 2), intraday RE remained below 5.7% (1) and 2.8% (2). 
Interday RE values predominantly remained under 3.0%, except for the lowest 
concentrations of 1 and 2, the highest variation being 21% for the lowest concentration of 
1. The RE values (both intraday and interday) of the flavonoids (3-6) were predominantly 
below 5%, and all below 15%. The only exception was the lowest of the standard 
concentrations of 5 (3.18 µM), which had much higher RE values (32%); thus, this 
concentration was below the LOQ as defined above. For each analyte measured, all 
standard concentrations above the LOQ resulted in an RE value of ≤ 15%. LOD values 
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for analytes 1, 2, 5, and 6 were all below 5 µM. LOD values for analytes 3 and 4 were 
higher (18 and 69 µM, respectively).  
 
 
 
Figure 3. UPLC separation of furanocoumarins. Numbered peaks correspond to the compounds in 
Fig. 2. (A) Furanocoumarin standards (659 and 640 μM, respectively) and (B) Juice A. 
 
Rapidity of Method 
Compared to HPLC analyses of furanocoumarins and flavonoids in the literature, 
the UPLC method described above markedly reduces the time required for the analyses 
of these compounds in grapefruit juice. A run time of 4.5 min represents an 80% 
reduction in the time required to analyze furanocoumarin content when compared with 
the most rapid published method,46 whereas a run time of 4.0 min represents an order of 
magnitude less time required for the analysis of flavonoids.47 Such methods facilitate the 
1
1
2
2
(A)
(B)
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determination of furanocoumarin and flavonoid concentrations in several grapefruit 
juices in a single day, reducing costs associated with both labor and materials. Moreover, 
the time saved expedites the characterization of juices used in in vitro or in vivo studies, 
thus accelerating the evaluation and determination of active constituents. 
 
 
Figure 4. UPLC separation of flavonoids. Numbered peaks correspond to the compounds in Fig. 
2. (A) Flavonoid standards (1080, 500, 800, and 800 μM, respectively) and (B) Juice A. 
 
4
3
6
5
(A)
3
4
56
(B)
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Table 1. Calibration curve data for analytes 1-6. 
Analyte Slope (± SD) r2 LOD a (µM) LOQ b (µM) 
1 4.338 × 103 (± 9) 
 
1.000  0.78 
 
2.6 
 2 3.784 × 103 (± 5) 
 
1.000  1.1 
 
3.8 
 3 9.04 × 102 (± 7) 
 
0.999  69 
 
230 
 4 9.98 × 102 (± 7) 
 
0.999  18 
 
58 
 5 1.626 × 103 (± 6) 
 
1.000  2.5 
 
8.4 
 6 8.95 × 102 (± 5)  1.000  3.9  13  
a Limit of detection 
b Limit of quantitation 
 
 
Concentrations of Analytes in Grapefruit Juices 
Five different grapefruit juices, four of which were commercially available 
products, were analyzed to measure the concentrations of selected furanocoumarins and 
flavonoids (Fig. 2). Samples were analyzed in the same run with the standards to 
eliminate concerns of systematic error introduced by day-to-day variability in instrument 
response. Each juice was analyzed using a 5-fold concentrated extract, and the reported 
values (Table 3) have been adjusted to reflect the concentration in the original juices. 
Considerable variation in the concentration of each compound was observed. Regarding 
the furanocoumarins, the concentrations of 1 and 2 in four of the juices ranged from 7.48 
(± 0.17) to 24.73 (± 0.16) µM and 7.65 (± 0.17) to 89.03 (± 0.17) µM, respectively. 
These values were consistent with those reported in the literature using HPLC.43, 45 The 
highest concentration of 2 (Juice C) was slightly higher than the ranges reported by De 
Castro et al.,43 though this was to be expected, as Juice C was a juice concentrate. 
Regarding the flavonoids, the concentrations of 3 and 4 ranged from 309 (± 15) to 1182 
(± 16) µM and 73.4 (± 4.8) to 286.5 (± 3.8) µM, respectively, which again were 
consistent with literature values using HPLC.41, 43  
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Table 2. Precision (RSD) and accuracy (RE) for analysis of analytes 1-6. 
Analytes 
Concentration of 
Standard Solution 
Injected (µM) 
Intraday  Interday 
RSD (%) RE (%)  RSD (%) RE (%) 
1 
10.3 
 
0.33 
 
5.7 
 
 3.1 
 
21. 
 20.6  0.27  
4.4 
 
 0.48 
 
8.5 
 41.2 
 
0.091 
 
1.6 
 
 0.31 
 
2.4 
 82.4 
 
0.19 
 
0.21 
 
 0.53 
 
1.1 
 165 
 
0.16 
 
0.03 
 
 0.26 
 
2.1 
 330 
 
0.29 
 
1.2 
 
 0.16 
 
0.83 
 659 
 
0.32 
 
0.29 
 
 0.32 
 
0.33 
        
 
    
2 
10 
 
0.15 
 
2.8 
 
 1.2 
 
9.2 
 20 
 
0.11 
 
1.1 
 
 0.67 
 
2.7 
 40 
 
0.017 
 
0.94 
 
 0.62 
 
0.69 
 80 
 
0.21 
 
0.10 
 
 0.56 
 
2.1 
 160 
 
0.16 
 
0.64 
 
 0.59 
 
2.5 
 320 
 
0.26 
 
0.70 
 
 0.61 
 
2.1 
 640 
 
0.31 
 
0.13 
 
 0.53 
 
1.4 
        
 
    
3 
649 
 
1.5 
 
15. 
 
 0.84 
 
17. 
 1081 
 
1.3 
 
4.6 
 
 0.14 
 
5.7 
 1802 
 
1.1 
 
0.81 
 
 0.38 
 
0.79 
 3003 
 
0.36 
 
3.3 
 
 0.45 
 
3.0 
 5005 
 
0.72 
 
3.6 
 
 0.29 
 
2.1 
 10010 
 
0.99 
 
1.0 
 
 0.28 
 
1.9 
        
 
    
4 
198 
 
1.6 
 
13. 
 
 0.67 
 
7.7 
 396 
 
2.6 
 
1.4 
 
 0.72 
 
2.1 
 792 
 
1.5 
 
1.6 
 
 0.43 
 
1.3 
 1584 
 
1.3 
 
2.5 
 
 0.26 
 
2.0 
 3168 
 
0.72 
 
0.66 
 
 0.78 
 
0.55 
        
 
    
5 
3.18 
 
1.4 
 
32. 
 
 0.03 
 
32. 
 12.7 
 
2.9 
 
9.7 
 
 0.32 
 
5.3 
 50.9 
 
1.4 
 
0.4 
 
 0.23 
 
1.4 
 203 
 
0.23 
 
1.6 
 
 0.35 
 
0.66 
 814 
 
1.2 
 
0.094 
 
 0.18 
 
0.39 
        
 
    
6 
  
3.12 
 
4.7 
 
2.4 
 
 3.1 
 
3.7 
 12.5 
 
0.64 
 
2.8 
 
 0.96 
 
8.3 
 49.9 
 
0.93 
 
3.5 
 
 0.69 
 
9.0 
 199 
 
0.71 
 
4.1 
 
 0.47 
 
8.1 
 798  1.6  3.0   0.72  1.4  
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Table 3. Concentrations of analytes 1-6 in grapefruit juices. 
Juice Concentrationa (µM) ± SD 
 
Bergamottin  
(1) 
DHBb  
(2) 
Naringin 
(3) 
Narirutin  
(4) 
Naringenin  
(5) 
Hesperidin 
(6) 
A 11.76 ± 0.16 41.31 ± 0.16 412 ± 15 100.5 ± 4.5 18.89 ± 0.66 NQ 
B NDc ND 309 ± 15 73.4 ± 4.8 ND NQ 
C 24.73 ± 0.16 89.03 ± 0.17 1182 ± 16 286.5 ± 3.8 34.72 ± 0.55 39.48 ± 0.83 
D 7.48 ± 0.17 7.65 ± 0.17 371 ± 15 85.2 ± 4.7 NQd NQ 
E 12.26 ± 0.16  11.58 ± 0.16  381 ± 15  103.5 ± 4.5  5.60 ± 0.79  NQ 
Each juice was analyzed in triplicate using a 5-fold concentrated extract, and the values 
reported have been adjusted to reflect the concentration in the juices, not in the extract. 
b 6′,7′-dihydroxybergamottin 
c Not detected 
d Indicates that the analyte was detected but was below the limit of quantitation 
 
 
The concentration of 6 ranged from below LOQ (although detected in all juices) 
to 39.48 (± 0.83) µM. The concentration of 5 ranged from below LOQ to 34.72 (± 0.55) 
µM, which agrees with literature values.62, 63 As with the furanocoumarins, the highest 
concentrations of the flavonoids were in Juice C. The concentrations of 1-4 in Juices A 
and B were measured previously using an HPLC method.4, 59 The concentration of the 
furanocoumarins (1 and 2) were consistent between methods (within 30 and 7%, 
respectively), whereas the concentrations of the flavonoids (3 and 4) by HPLC were 
approximately 2-fold higher than those by UPLC. Reasons for this difference remains 
unexplored, as a between-laboratory validated study was beyond the scope of this work. 
The extracts used in this study were analyzed at a 5-fold concentration. In the future, the 
accuracy of the measurements for analytes present in very low concentrations could be 
improved by using a more concentrated extract. 
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Wide between-juice variation in the concentrations of each grapefruit juice 
constituent was observed, as would be expected for natural products, and the 
concentrations agreed well with values reported in the literature using HPLC. This 
marked variation between commercially available brands undoubtedly contributes to the 
large between-study differences in effect size (i.e., change in drug area under the curve 
[AUC]) associated with clinical grapefruit juice-drug interaction studies.7 Quantitation of 
one or more constituents in a given juice would provide a means for between-study 
comparisons of clinical, as well as in vitro, data. The UPLC methods developed in the 
current work offer a rapid means for the quantitation of representative constituents. While 
the methods were applied to grapefruit juices, they should be applicable to other foods, 
including other fruit juices. 
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CHAPTER III 
LABELED CONTENT OF TWO FURANOCOUMARINS IN DIETARY 
SUPPLEMENTS CORRELATES WITH NEITHER ACTUAL CONTENT NOR 
CYP3A INHIBITORY ACTIVITY 
 
     This chapter is intended for submission to the journal Pharmaceutical and Biomedical     
     Analysis and is presented in that style. Coauthors include Garrett R. Ainslie, Mary F.  
     Paine, and Nicholas H. Oberlies. 
 
 
Introduction 
Dietary supplements are a thriving industry in the United States, surpassing $30 
billion in sales in 201164 and encompassing various facets of the market. They can 
include single- or multi-vitamins, minerals, herbs and botanicals,65 weight-loss aids, and 
sports nutrition products. Of these, sports nutrition supplements made up 12% of the total 
sales.64, 66 Some of these supplements are labeled to contain 6′,7′-dihydroxybergamottin 
(DHB) and/or bergamottin (Fig. 1), two furanocoumarins normally found in grapefruit 
juice, that have been shown to interfere with cytochrome P450 3A (CYP3A) in the 
intestine through irreversible inhibition of the enzyme.3, 4, 6, 21  
Intestinal CYP3A contributes significantly to the pre-systemic (‘first-pass’) 
metabolism of numerous orally-administered drugs, including felodipine, lovastatin, and 
cyclosporine.4-7 Inhibition of intestinal CYP3A by furanocoumarins can increase the 
systemic exposure of these ‘victim’ drugs to an extent that leads to side effects ranging
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from relatively mild (e.g., hypotension and dizziness with some calcium channel 
blockers) to potentially severe (e.g., nephrotoxicity with some immunosuppressants). 
CYP3A also is involved in the oxidative metabolism of both endogenous and exogenous 
androgens, including testosterone11 and synthetic steroids marketed as legal body 
building supplements. For example, two synthetic steroids in the supplements Finaflex 1-
Andro and Finaflex 1-Alpha included 3-hydroxy-5α-androst-1-ene-17-one and 3-
enanthoxy-5α-androst-1-ene-17-one, respectively. These additives can be sold as 
mixtures labeled to contain DHB and/or bergamottin, allegedly enhancing the effect of 
the steroids by “mak[ing] the active ingredient more bio-available” (Finaflex 1-Andro). 
At least one supplement, SciFit DHB 300, was labeled to contain 300 mg of pure DHB in 
each capsule, and was presumably intended to be taken concomitantly with other 
products of the consumer’s choice. Grapefruit juice contains between 0.2 and 89.0 µM 
DHB and 2.5 and 36.3 µM bergamottin,43, 45, 67 equating to between 0.02 to 7.4 mg DHB 
and 0.2 to 2.9 mg bergamottin per 8-oz (240-mL) serving. Grapefruit juice containing 2.7 
mg DHB and 2.2 mg bergamottin per 240-mL serving doubled median area under the 
curve of felodipine relative to control.4 Supplements containing DHB or bergamottin at 
similar amounts may pose a risk for consumers taking concomitant medications that 
undergo extensive CYP3A-mediated intestinal metabolism.4-7 
Other dietary supplements have been shown to modulate drug metabolism with 
subsequent unwanted effects, most notably Hypericum perforatum L. (St. John’s wort). 
Opposite to grapefruit juice, St. John’s wort induces the expression68 of intestinal (and 
hepatic) CYP3A, as well as P-glycoprotein (P-gp), an apically-located transmembrane 
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efflux protein that transports susceptible substrates back into the intestinal lumen or into 
bile.19 Induction of CYP3A and P-gp can decrease significantly the systemic exposure 
and efficacy of diverse drugs, including oral contraceptives, cyclosporine, and 
methadone.69-72 The risk of supplement-drug interactions is exacerbated by both the lack 
of pre- and post-launch scrutiny of supplements,65, 73 as well as chronic underreporting of 
supplement use by patients.74-77  
To address the possibility of dietary substance-drug interactions perpetrated by 
supplements containing DHB or bergamottin, both quantitative analysis and a CYP3A 
inhibitory activity bioassay were employed. The quantification method utilized ultra-
performance liquid chromatography (UPLC) for rapid (3.0 min) separation of the 
supplement extracts, coupled to both a photodiode array detector (PDA) and a triple 
quadrupole mass spectrometer (MS) for quantification. Based on a previously published 
study,67 this method was refined for faster analysis and made use of the MS to identify 
more easily the analyte peaks in the complex extracts. The quantification was used to 
evaluate the labeled vs. actual content of DHB and bergamottin in selected supplements, 
while the bioassay was used to assess whether the actual content of the furanocoumarins 
correlated with CYP3A inhibitory activity. 
 
Materials and Methods 
Chemicals and Materials 
6′,7′-Dihydroxybegamottin was purchased from Sigma-Aldrich (purity ≥ 97.2%) 
and Cayman Chemical (Ann Arbor, MI; purity ≥ 98.0%); bergamottin was purchased 
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from ChromaDex (Irvine, CA; purity ≥ 96.9%) and Sigma-Aldrich (St. Louis, MO; purity 
≥ 98.0). Midazolam (purity ≥ 99.9%), 1-hydroxymidazolam (purity ≥ 98.0%), 
ketoconazole (purity ≥ 98.0%), alprazolam (purity ≥ 99.0%), and NADPH were 
purchased from Sigma-Aldrich. Purity of standards is reported as determined by HPLC 
(TLC in the case of alprazolam) by the manufacturers. Methanol (MeOH) was purchased 
from Pharmco-Aaper (Shelbyville, KY) and Fischer Scientific (Waltham, MA). UPLC-
grade water (H2O) and acetonitrile (CH3CN) were purchased from Fisher Scientific. 
Pooled human intestinal microsomes (HIM) (n = 18 donors) were purchased from 
Xenotech (Lenexa, KS). 
 
Supplements Analyzed  
Six supplements labeled to contain DHB or bergamottin were selected: SciFit 
DHB 300 (SciFit, Oakmont PA; lot 57454), Trisorbagen (Anabolic Xtreme, Tempe AZ; 
lot 202609), Xceler8 DHB (VitaSport, Chino Hills CA; lot US 37700), AttentionLink 
(Hi-Tech Pharmaceuticals, Inc., Norcross GA; lot 08132039), Finaflex 1-Alpha 
(Redefine Nutrition, Alpharetta GA; lot 824912013), and Finaflex 1-Andro (Redefine 
Nutrition, Alpharetta GA; lot 0500313). Five capsules from each product were analyzed 
quantitatively; an additional five capsules from each product were tested in CYP3A 
inhibition assays (Section 2.7). With the exception of AttentionLink, all capsules were 
opened and their contents weighed. Because the AttentionLink capsules contained a 
viscous material encased in a microcrystalline cellulose outer layer, they were weighed in 
their entirety (Appendix, Table S1).  
 
25 
Extraction of Supplements  
The contents of the capsules (and in the case of AttentionLink, the entire capsule) 
were shaken for 5 h at 100 rpm in 3.0 mL of MeOH. Aliquots (600 mL) of the extract 
were filtered using 1.7 mL polypropylene Spin-X centrifuge tube filters (0.22 µm) and 
centrifuged for 10 min at 14 × 103 rpm. This method was modified from a study 
measuring furanocoumarins in teas, fruits and vegetables that found MeOH to be the 
most efficient solvent.78 
 
Preparation of Standards  
Bergamottin and DHB were dissolved in MeOH to create stock solutions of 1.6 
mM each. Two calibration curves containing both standards were prepared form these 
stocks solutions. One standard curve (PDA curve) used six concentrations ranging from 
5.00 µM to 160.0 µM for both bergamottin and DHB; the second standard curve (MS 
curve) used five concentrations ranging from 0.313 µM to 5.00 µM for both bergamottin 
and DHB. 
 
UPLC-PDA-MS Analysis  
UPLC separations of the stock solutions and supplement extracts were performed 
using a Waters Acquity UPLC system (Milford, MA) equipped with an autosampler, 
photodiode array detector (PDA), column manager, and binary solvent manager. An HSS 
C18 column (50 mm × 2.1 mm i.d., 1.8 µm, Waters, Milford, MA) was used for all 
chromatographic separations, held at a constant temperature of 40 °C. The gradient 
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system consisted of A, 0.1% formic acid in CH3CN and B, 0.1% formic acid in H2O, at a 
flow rate of 0.6 mL/min: 0-1.2 min, 30-60% A; 1.2-2.0 min, 60-100% A; 2.0-3.0 min, 
100% A. Both standards and samples were injected in triplicate, at a volume of 2.0 µL. 
The UPLC system was coupled to a Thermo Scientific TSQ Quantum Access 
triple quadrupole mass spectrometer (Waltham MA) with a heated electrospray ionization 
(HESI) source. Analyses were conducted in positive mode, with spray voltage 3800 V, 
vaporizer and capillary temperatures 300 °C and 350 °C, respectively, sheath gas and 
auxiliary gas 45 and 35 (arbitrary units), respectively. Tube lens offset and skimmer 
offset were 89 and 0, respectively. The mass spectrometer was calibrated externally using 
polytyrosine. Data were collected on the mass spectrometer using full scan mode, using a 
scan time of 0.3 s, and mass range of 150-500 m/z; data were collected at 250 nm on the 
PDA. All data were analyzed using Xcalibur V2.2 software.  
 
Method Validation  
Linearity of the calibration curves was assessed by least-squares analysis. 
Precision and accuracy were determined by calculating the relative standard deviation 
(RSD) and relative error (RE), defined as the percent difference between the mean 
observed concentration and the nominal concentration, of three replicate analyses of the 
standards. All analyses of the extracts were performed in triplicate on a single day. 
Interday RSD and RE were determined by analyzing the standard solutions in triplicate 
on three separate days. The limit of detection (LOD) and limit of quantification (LOQ) 
were defined as 3.3s/m and 10s/m, respectively (where s is the standard deviation of the 
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response and m is the slope of the calibration curve), as per the guidelines set forth by the 
International Conference on Harmonisation (ICH).79  
Matrix effect was evaluated by comparing the relative responses of analyte spiked 
into a MeOH blank and the supplement extracts.80 A 2.5 µL aliquot of a 20 mM 
bergamottin and DHB solution was added to 497.5 µL of MeOH and supplement extract; 
a 2.5 µL aliquot of MeOH was added to 497.5 µL of the same supplement extracts to 
provide a comparison to the unspiked supplements. The analyte peak areas of the spiked 
supplements (S) minus the peak areas of the unspiked supplements (U) were compared to 
the average peak area of the spiked MeOH (M) and expressed as a percent recovery: (S-
U)/M×100. Extraction efficiency was evaluated by adding 30 µg of bergamottin and 
DHB to four capsules of each supplement. The supplements were extracted as described 
in Section 2.3 and quantification was performed as described in Section 2.5. The average 
amount measured in unspiked capsules was subtracted from the amount measured in 
spiked capsules, and the remainder was used to calculate percent recovery. 
 
CYP3A Inhibition Assays  
A dilution scheme was devised using the product with the highest measured 
amount of DHB (SciFit DHB 300). The corresponding extract was reconstituted with 130 
µL MeOH, which was diluted 1:10 in MeOH. Each of these methanolic solutions was 
diluted further into incubation mixtures (see below) to yield final DHB concentrations of 
1 and 0.1 μM; the higher concentration approximates the Ki of DHB towards CYP3A 
using human intestinal microsomes (HIM) and midazolam as the probe substrate.11 All 
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other supplements were reconstituted and diluted in the same manner as SciFit DHB 
300.The final concentration of MeOH (1.0%) was the same in all incubations. 
Midazolam (4 µM) was incubated with (0.05 mg/mL protein) for 4 min at 37°C in the 
presence of diluted extracts, DHB, bergamottin, ketoconazole, or vehicle control; the 
final concentrations of DHB, bergamottin, and ketoconazole were 1 and 0.1 μM. 
Reactions were initiated with nicotinamide adenine dinucleotide phosphate (1 mM final 
concentration) and were terminated by removing a 100-µL aliquot and adding to 300 µL 
of ice-cold CH3CN containing an internal standard (300 µg/mL alprazolam). Samples 
were vortexed (~30 s) and centrifuged (3000 g × 10 min at 4 °C), after which 100 µL of 
supernatant were removed and analyzed for 1′-hydroxymidazolam by LC-MS-MS on an 
API 6500 QTrap operated in MRM mode and equipped with an electrospray ionization 
source. Calibration standards were matrix-matched and were linear from 3.9 to 2000 nM. 
The QTrap was coupled to a Shimadzu Nextera UHPLC system (Kyoto, Japan). 
Chromatographic separation of midazolam, 1′-hydroxymidazolam, and alprazolam was 
achieved on a Thermo Scientific Aquasil C18 (2.1 × 50 mm, 3 µm) HPLC column 
(Waltham, MA) using a gradient method following a 7-µL injection of each supernatant. 
The gradient system consisted of A, 0.1% formic acid in CH3CN and B, 0.1% formic acid 
in H2O, at a flow rate of 0.75 mL/min: 0-0.4 min, 5% A; 0.4-1.5 min, 5-95% A; 1.5-2.1 
min, 95% A; 2.1-2.11, 95-5% A; 2.11-3.0, 5% A. Sample and column temperatures were 
4°C and 40°C, respectively. Quality controls (QC) of 10, 100, and 1500 nM were used to 
assess accuracy. All standards and (QC) were accurate to within 20% of the nominal 
value; QC precision was <15% RE.    
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Results and Discussion 
Method Validation  
The PDA calibration curve (5.00 µM to 160.0 µM) showed excellent linearity in UV 
response (DHB R2 = 0.9996, bergamottin R2 = 0.9995); however, the MS response 
exhibited a limited linear dynamic range (0.156 µM to 5.00 µM). Because of the latter, 
the UV detection was used to analyze supplements with analytes corresponding to the 
higher concentration range. The second curve (0.156 µM to 5.00 µM) was linear in both 
the UV (DHB R2 = 0.9993, bergamottin R2 = 0.9966) and MS (DHB R2 = 0.9977, 
bergamottin R2 = 0.9968) response; due to the superior resolving power of MS, afforded 
by the ability to select for specific m/z, the MS signals were used to quantify supplements 
with analyte concentrations in this range. The LODs were 0.073 µM (DHB) and 0.10 
(bergamottin) for the PDA curve and 0.054 µM (DHB and bergamottin) for the MS 
curve. The LOQs were 0.22 µM (DHB) and 1.8 µM (bergamottin) for the PDA curve and 
0.16 µM (DHB and bergamottin) for the MS curve. Parameters for the standard curves 
are summarized in Table 4. When converted to µg/capsule, the LODs were 0.074 µg 
(DHB) and 0.12 (bergamottin) for the PDA curve and 0.060 µg (DHB and bergamottin) 
for the MS curve, while the LOQs were 0.22 µg (DHB) and 2.0 µg (bergamottin) for the 
PDA curve and 0.18 µg (DHB and bergamottin) for the MS curve. 
Intraday precision in the PDA curve was below 1.0% for both analytes (Table 5) 
except at one concentration (10 µM), which had an RSD of 8.0%. Interday precision for 
the same standard curve ranged from 1.2 to 5.9%. The RE for both analytes, both intra 
and interday, was below 5.8%. The measurements from the MS curve (Table 6) had 
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slightly higher RSDs (ranging from 1.2 to 5.4% intraday and 1.4 to 7.0% interday); 
whether this decrease in precision was inherent to the MS detector or a consequence of 
the much lower concentrations in the standard curve is unknown. The RE for both 
analytes was, in general, below 5.4%, with a maximum RE of 8.0% for bergamottin and 
6.7% for DHB.  
 
Table 4. Parameters of calibration curves. 
  Analyte Slope (± SD) r
2 
LOD 
(µM) LOQ (µM) 
PDA Curve 1 4.087 × 103 (± 24) 0.9995  
0.10 
 
1.8 
 (5.00 µM to 160.0 µM) 2 2.451 × 103 (± 9) 0.9996  0.073 
 
0.22 
 
 
     
 
 
 MS Curve 1 2.101 × 106 (± 2.7 × 104) 0.9968  
0.054 
 
0.16 
 (0.313 µM to 5.00 µM) 2 2.729 × 106 (± 4.5 × 104) 0.9977   0.054   0.16   
 
Table 5. Intra and interday precision and accuracy of the PDA curve. 
Analytes 
Concentration of 
Standard Solution 
Injected (µM) 
Intraday   Interday 
RSD (%) RE (%)   RSD (%) RE (%) 
1 
160 
 
0.52 
 
5.8 
 
 
3.0 
 
4.3 
 80.0 
 
0.40 
 
3.8 
 
 
2.3 
 
1.1 
 40.0 
 
0.58 
 
0.69 
 
 
2.3 
 
2.1 
 20.0 
 
0.47 
 
1.9 
 
 
1.9 
 
4.0 
 10.0 
 
0.20 
 
3.7 
 
 
3.8 
 
1.7 
 5.00 
 
3.6 
 
1.2 
 
 
3.7 
 
2.5 
             
2 
160 
 
0.47 
 
0.64 
 
 
0.44 
 
0.81 
 80.0 
 
0.37 
 
1.3 
 
 1.2 
 
2.1 
 40.0 
 
0.32 
 
3.8 
 
 
5.3 
 
3.1 
 20.0 
 
1.9 
 
4.8 
 
 
4.4 
 
3.7 
 10.0 
 
8.0 
 
3.4 
 
 5.9 
 
0.65 
 5.00   0.45   1.0     1.4   1.9   
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Table 6. Intra and interday precision and accuracy of MS curve. 
Analyte 
Concentration of 
Standard Solution 
Injected (µM) 
Intraday   Interday 
RSD (%) RE (%)   RSD (%) RE (%) 
1 
5.00 
 
4.4 
 
1.2 
 
 
4.3 
 
2.8 
 2.50 
 
3.0 
 
2.4 
 
 
3.7 
 
2.2 
 1.25 
 
4.6 
 
5.2 
 
 
4.5 
 
5.4 
 0.625 
 
4.9 
 
8.0 
 
 
7.0 
 
2.7 
 0.313 
 
5.4 
 
3.2 
 
 
5.4 
 
0.35 
             
2 
5.00 
 
1.7 
 
1.6 
 
 
1.4 
 
1.3 
 2.50 
 
1.2 
 
4.6 
 
 
2.1 
 
3.8 
 1.25 
 
1.8 
 
6.7 
 
 3.4 
 
4.3 
 0.625 
 
4.6 
 
1.6 
 
 
3.8 
 
4.3 
 0.313   2.7   2.9     4.9   3.1   
 
Except for Xceler8 DHB, matrix effects (expressed as percent recovery) were all 
within 15% (Table 7). Because of the substantial matrix effect of Xceler8 DHB, further 
analysis of this supplement, including quantification and in vitro testing, is not reported 
here. Extraction efficiency was above 84.8% (± 1.1) for all supplements tested, with one 
exception; AttentionLink demonstrated 77.7% (± 3.7) recovery of bergamottin (Table 8). 
 
Table 7. Matrix effects, expressed as mean recoveries of spiked analyte in supplement extracts. 
 % Recovery (± SD) 
 
Bergamottin  DHB 
SciFit DHB 300 97.1 (± 4.9)  
 
102.2 (± 9.2)  
Trisorbagen 100.2 (± 4.9)  
 
99.3 (± 8.1)  
Xceler8 DHB 9.2 (± 1.9)  
 
9.54 (± 0.80)  
AttentionLink 85.9 (± 6.7)  
 
102.0 (± 3.0)  
Finaflex 1-Alpha 100.5 (± 1.9)  
 
104.1 (± 5.3)  
Finaflex 1-Andro 88.2 (± 5.9)  
 
87.5 (± 5.4)  
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Table 8. Extraction efficiency, expressed as mean recoveries of spiked analyte, in supplement 
extracts. 
 
 % Recovery (± SD) 
 
Bergamottin 
 
DHB 
SciFit DHB 300* 101. (± 12.)  
 
100.1 (± 7.0)  
Trisorbagen 90.4 (± 1.1)  
 
84.8 (± 1.1)  
AttentionLink 77.2 (± 3.7)  
 
99.7 (± 4.3)  
Finaflex 1-Alpha 93.49 (± 0.80)  
 
98.0 (± 3.2)  
Finaflex 1-Andro 98.6 (± 5.1)  
 
86.7 (± 3.1)  
 
*The percent recovery for SciFit DHB 300 was calculated as the amount measured in a spiked capsule 
minus the average amount of analyte measured in unspiked capsules (12.13 (± 0.23) µg bergamottin and 
65.51 (± 0.64) µg DHB).        
 
Quantification of Bergamottin and DHB in Dietary Supplements  
Of all the supplements analyzed, only two had detectable amounts of bergamottin 
and DHB (Appendix, Table S2). The SciFit DHB 300 capsules, the label for which 
claimed 300 mg pure DHB, contained an average of 12.13 (± 0.23) µg bergamottin and 
65.51 (± 0.64) µg DHB per capsule. Bergamottin was detected in Xceler8 DHB, but due 
to substantial matrix effects (Section 3.1, Table 7) the quantification is not reported here. 
Complete per-capsule data are available in the Appendix, Table S2.  
 
CYP3A Inhibition Assay  
Vehicle control reaction velocities of 416 ± 29 pmol/min/mg protein 
demonstrated acceptable CYP3A activity in the HIM lot used. The CYP3A inhibitor, 
ketoconazole, abolished 1’-hydroxymidazolam formation at 1 µM and inhibited activity 
by ~80% at 0.1 µM (Fig. 5). Bergamottin showed no inhibition at the concentrations 
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tested (Fig. 5). This lack of effect by bergamottin was expected at these concentrations 
based on an apparent Ki >10 µM with HIM.11 DHB at 0.1 and 1 µM inhibited activity by 
5 and 42%, respectively. Except for bergamottin, concentration dependency was 
observed for each treatment (p<0.05; 2-way ANOVA with Bonferroni adjustment).  
 
 
 
Figure 5. Comparison of the effects of various supplements labeled to contain DHB with known 
CYP3A inhibitors on CYP3A activity in human intestinal microsomes. DHB, bergamottin, and 
ketoconazole were tested at 0.1 µM (white) or 1 µM (black). The methanolic extract of SciFit was 
tested such that the final concentration of DHB was 0.1 or 1 μM. All other methanolic extracts 
were tested at the same dilutions as SciFit. Bars and error bars denote the means and SDs, 
respectively, of triplicate incubations. Inhibition by 1 µM ketoconazole was below the limit of 
quantification. *p < 0.05 between supplement extracts; #p < 0.05 versus 1µM DHB standard; Ŧp < 
0.05 versus 0.1 µM DHB standard. Statistical comparisons were made via two-way ANOVA with 
a Bonferroni adjustment.  
 
Because the extract dilutions were based on the measured DHB content in the 
SciFit DHB 300 supplement, this supplement was expected to behave most like authentic 
DHB. However, this supplement was approximately two-fold more potent than DHB 
(Fig. 5). In addition to SciFit, two supplements (Trisorbagen and AttentionLink) 
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demonstrated potent inhibition of CYP3A activity despite very low measured amounts of 
DHB and bergamottin. Finaflex 1-Alpha appeared to stimulate CYP3A activity at the 
lower concentration, which has been observed with low concentrations of bergamottin (< 
2.5 μM) in incubations with HIM and midazolam.12 Lastly, an inverse relationship 
between dose and response was observed with Finaflex 1-Andro. 
 
Conclusions 
The quantity of DHB measured in one SciFit capsule (0.065 mg) was 
considerably less than that in a glass of grapefruit juice (2.1 to 3.8 mg) used in clinical 
studies reporting a significant increase in victim drug systemic exposure when co-
administered with the juice.4, 81-83 A consumer would have to take 32 capsules of SciFit to 
achieve a dose of DHB equivalent to the lowest effective concentration reported in 
clinical studies.82 Despite the expectation that the supplements would lack CYP3A 
inhibitory activity, several of the extracts were more potent than DHB alone, indicating 
additional CYP3A inhibitors present in the supplements. Trisorbagen, for example, was 
labeled to contain a standardized piperine composition, though it did not report actual 
quantities; piperine has been demonstrated previously to inhibit CYP3A activity in 
human liver microsomes (Ki ~40 µM) and may be involved in the aforementioned in vitro 
activity.84 Whether such activity translates to the clinical setting remains to be 
determined. Further analysis of the supplements would provide additional insight by 
identifying the constituents responsible for the unexpected inhibitory potency.  
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  CHAPTER IV 
 DRUG DISCOVERY OF MICROBIAL METABOLITES  
Natural products as a source of lead compounds for drug discovery 
Microorganisms and plants have evolved to produce wide varieties of compounds 
that cause a biological effect in other organisms85 – what some researchers have likened 
to a chemical arms race.86, 87 Such natural products have been naturally selected to 
provide array of highly varied and diverse compounds evolved expressly for interactions 
with biological macromolecules.88  
Despite the surge in popularity of combinatorial chemistry as a source for high-
throughput screening libraries, natural products and their derivatives remain a large 
majority of both new chemical entities (NCEs) and approved drugs,89 likely due to the 
aforementioned inherent diversity and affinity for biological targets.88, 90 When compared 
to the libraries of compounds manufactured by combinatorial chemistry, the chemical 
diversity of natural products has been shown to be significantly greater;91, 92 key features 
shared by natural products and current drugs, such as the number of chiral centers, that 
confer the biological specificity crucial to both secondary metabolites and medications, 
are often lacking in the products of combinatorial synthesis.93 
Of all the NCEs discovered in the last 30 years, only 29% were completely 
synthetic in origin; disregarding the biologics and vaccines, natural product compounds 
accounted for ~50% of the small-molecule NCEs.94  Of the antiinfectives approved in
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that time span, natural product-derived compounds make up 77% of the total, and 68% of 
the small molecule antiinfectives.94 It is noteworthy that the synthetic antiinfective drugs 
tend to fall into two chemotypes, including the azole-based antifungals, and the 
quinolone-based antibacterials.89 Of the currently available small-molecule cancer drugs, 
74% are natural product-derived; if the biologically-derived compounds are included, this 
number rises to 78%. More striking is the fact that natural product-derived compounds 
make up 79% of new small molecule anticancer drugs approved between 1981 and 
2010.94 Indeed, the only de novo combinatorial drug approved by the FDA is sorafenib 
mesylate, which entered the market in 2005 for the treatment of advanced renal cancer. 
While combinatorial chemistry is a powerful tool for optimizing known 
compounds, natural products remain the primary source of new chemical diversity. 
Several problems associated with natural products screening that originally caused 
pharmaceutical companies to turn instead to combinatorial libraries (i.e. speed of 
isolation, identification of active compounds, rediscovery of known compounds, etc.) are 
being addressed by advances in both technology91 and techniques.95 To address the ever-
present need for new active compounds, the wealth of secondary metabolites produced by 
the natural world must be explored. 
 
The role of fungi as source of biologically active secondary metabolites 
Historically, fungi have provided the human population with a broad range of 
medications, ranging from antibiotics such as the penicillins to the cholesterol-lowering 
drugs based on mevinolin (Lovastatin).96 More recently, fingolimod, derived from a 
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fungal secondary metabolite, was approved for the treatment of multiple sclerosis,97 and 
trials are ongoing for the use of psilocybin as a treatment for anxiety in cancer patients.98 
Caspofungin, introduced to the market in 2001 as a treatement for refractory invasive 
aspergilloses, represented the first new class of systemic antifungal agents to be approved 
in 25 years.99 Despite the success of these and similar lead compounds, only a fraction of 
the available fungal diversity has been studied. While estimates of fungal species range 
from 0.5 million100 to 9.9 million,101 the commonly cited conservative estimate is that at 
least 1.5 million fungal species exist currently, with only 75,000 of these being described 
in the literature.102 Accessing new ranges of biological diversity inevitably leads to the 
discovery of new (and often unique) natural products.91 The recent foray into endophytic 
fungi has produced several new groups of compounds;103, 104 it can only be inferred that 
exploring further into the huge breadth of the fungal world will provide additional 
families of molecular scaffolds, with the hopeful outcome of discovering new lead 
compounds for future drugs.  
 
Mining suppressed genes can lead to new natural products 
Fungal secondary metabolites are produced via several key pathways, involving 
polyketide synthases (PKSs), non-ribosomal peptide synthases (NRPSs), hybrid PKS-
NRPS (HPN), as well as pathways coding for terpenes and indole alkaloids.105 In fungi, 
these genes are often found in clusters, a fact that has implications on the transcription 
and regulation of secondary metabolite pathways. With the recent advent of complete 
fungi genome sequences,106-109 it has become clear that the number of gene clusters 
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encoding these pathways greatly outnumbers the known secondary metabolites for these 
organisms.110 A study on the sequence of Aspergillus niger demonstrated that less than 
30% of its PKS-NRPS-, and HPN-encoding gene clusters were transcriptionally active.111 
This transcriptional suppression has led to a variety of studies delving into the 
mechanisms of transcriptional regulation, as well as techniques designed to “unlock” 
these suppressed pathways. 
Regulation of gene cluster transcription is a complicated, and not fully 
understood, process, involving many different transcription factors and a variety of 
epigenetic influences. Transcription factors affecting secondary metabolite production 
fall into two categories: narrow, or pathway-specific transcription factors, and broad 
domain transcription factors.112 The first pathway-specific factor identified was AflR, in 
1993, from a strain of Aspergillus parasiticus,113 and has since become a model for 
understanding such factors and their role in cluster regulation. Like most pathway-
specific factors, aflR is found embedded within the gene cluster that it regulates;114 
deletion or mutation of the gene suppresses expression of sterigmatocystin and aflatoxin 
cluster genes,113 while insertion of additional copies of aflR induces increased gene 
expression.115 Broad domain transcription factors respond to changes in environmental 
conditions, such as carbon,116 nitrogen,117 and pH.118 Both negative and positive 
regulation of gene clusters have been evidenced for each of these conditions and their 
corresponding transcription factor proteins.112  
A more recent insight into the regulation of secondary metabolite gene 
transcription involved the discovery of an Aspergillus methyltransferase, LaeA.119 
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Deletion of laeA in A. nudulans, A. fumigatus, and A. terreus strains repressed the 
production of several secondary metabolites through the transcriptional silencing of their 
encoding genes, while overexpression of laeA increased the production of these same 
compounds.119 Unlike many other genes that regulate secondary metabolism, the loss of 
laeA did not significantly impact the developmental process of the fungi,119 indicating the 
possibility of using other epigenetic modification to access similar metabolite pathways 
that are normally transcriptionally silent. 
Such efforts have begun in the form of small-molecule chemical epigenetic 
modification. In the normal transcription process, a number of small molecule 
modifications of the histone proteins in chromatin affect the transcriptional availability of 
the DNA. Within the chromatin structure, DNA is tightly coiled around core histone 
proteins, forming nucleosomes; linker histones bind nucleosomes together as chromatin. 
Methylation, acetylation, phosphorylation, ADP-ribosylation, or ubiquitination of the 
histone N-terminal tail regions affect the binding of the histone proteins to DNA, 
changing the structure of the chromatin and subsequently the accessibility of transcription 
factors to DNA regions.120 By altering these processes, it is possible to affect the 
transcription of the genes that they regulate.  
The most frequently studied and best understood epigenetic process is histone 
acetylation. Histone acetylation is controlled by the enzymes histone acetyltransferases 
(HATs) and histone deacetylases (HDACs). HATs direct the addition of acetyl groups to 
lysine residues in the amino-terminal histone tails, neutralizing that portion of the protein 
and relaxing the chromatin structure, thereby increasing accessibility of transcription 
 
41 
complexes as well as recruiting transcription cofactors.120-123 Conversely, HDACs 
remove acetyl groups from the histone tails, resulting in a more compact and inaccessible 
form of chromatin, consequently silencing transcription.120-122  
DNA itself can also be posttranslationally modified; in fungi this process is 
regulated by DNA methyltransferases (DNMTs). DNMTs add a methyl group to 
cytosine, resulting in a 5-methylcytosine product, altering gene transcription124, 125 by 
affecting the recognition of DNA sequences by transcription factors. DNMT inhibitors 
tend to be nucleoside analogues that become incorporated into DNA during replication. 
DNMTs bind irreversibly to the analogue base, thus depleting the enzymes and reducing 
DNA methylation. This decrease in DNA methylation results in additional gene 
activation.126  
Recently, efforts have been made to manipulate the epigenetic regulation of gene 
transcription by growing fungal strains in the presence of various small-molecule drugs. 
Such research has focused mainly on HDAC inhibitors111, 127-129 and DNMT inhibitors,111, 
129-131 in order to make more transcriptionally available the genes that these proteins 
normally help to suppress. Treatment of Aspergillus alternata and Penicillium expansum 
with the HDAC inhibitor trichostatin A (TSA) resulted in increased production of 
numerous secondary metabolites.127 A similar study using the HDAC inhibitor 
suberoylanilide hydroxamic acid (SAHA) to treat Aspergillus niger resulted in the 
isolation of a new metabolite, nygerone A, containing a unique 1-phenylpyridin-4(1H)-
one core that previously had not been reported from any natural source.128 Treatment of 
Penicillium citreonigrum with the DNMT inhibitor 5-azacytidine (5-AZA) produced ten 
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additional secondary metabolites, including two new compounds.130 New compounds 
have also been isolated from a SAHA-treated growth of Cladosporium cladosporioides 
and a 5-AZA-treated growth of a Diatrype species.129 The effects of SAHA and 5-AZA 
on Apergillus niger gene expression were further characterized by using real-time 
quantitative reverse-transcription PCR to analyze the change in expression of PKS, 
NRPS, and HPN pathways when treated with the epigenetic modifiers.111 In this study, all 
but seven of these 55 gene clusters showed increased transcriptional rates.  
 
Aims of this project 
The investigations described here utilize two approaches to maximize the 
genomic potential of fungi. One study investigates the impact of media on the production 
of fungal secondary metabolites.  It has been shown that the manipulation of environment 
and nutrition can have substantial impacts on the quantity and diversity of secondary 
metabolite production,132-139 and optimization of this initial step may have profound 
effects on the output and success of a natural products screening program.  
 The second study makes use of the proteasome inhibitor bortezomib (Fig. 6) as 
an epigenetic modifier to induce the transcription of silent secondary metabolite genes. 
Initial research on the epigenetic modification of fungi has focused on agents that directly 
target the transcription of genes. HDAC inhibitors cause chromatin to become more open 
and transcriptionally active; DNMTs alter gene transcription by posttranslationally 
modifying DNA. Bortezomib affects the transcriptional process by inhibiting 
proteasomes, which are large protein complexes responsible for the degradation of 
 
43 
proteins by proteolysis. Among the many proteins degraded by the proteasome pathway, 
several transcriptional regulators have been identified,140, 141 implicating proteasomes as a 
crucial player in the complicated functions of gene transcription.  
 
 
Figure 6. The proteasome inhibitor, bortezomib.  
 
There are no references in the current literature describing the use of bortezomib, 
or any proteasome inhibitor, as an epigenetic modifier to induce the production of new 
secondary metabolites in fungus.  
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CHAPTER V 
EVALUATION OF CULTURE MEDIA FOR THE PRODUCTION OF SECONDARY 
METABOLITES IN A NATURAL PRODUCTS SCREENING PROGRAM 
 
     This chapter has been published in AMB Express and is presented in that style.  
     VanderMolen, K.M., Raja, H.A., El-Elimat, T., Oberlies, N.H. Evaluation of Culture Media  
      for the Production of Secondary Metabolites in a Natural Products Screening Program. AMB  
     Express. 2013. 3:71. 
 
 
Introduction 
Fungi provide a plentiful and diverse source of unique and often bioactive 
metabolites, and they have produced a number of medicinally important compounds, 
including penicillin, mevinolin (Lovastatin),96 fingolimod,97 and caspofungin.99 The 
search for new and active compounds from microbial sources is a pursuit for many 
natural products laboratories. Typically, these efforts will employ a standard culture 
procedure that most or all microbial strains pass through as a preliminary step to the 
natural products discovery process. The manipulation of environment and nutrition has 
been shown to have substantial impacts on the quantity and diversity of secondary 
metabolite production,132-139 and optimization of this initial step, the microbial culture, 
may have profound effects on the output and success of a natural products screening 
program.  
Methodical modification of culture growing conditions is often referred to as the 
OSMAC (one strain, many compounds) approach.132, 142 This concept is ideal for fully
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exploiting the metabolomic diversity of a single or handful of organisms, but it becomes 
cumbersome when applied to a large-scale screening program. Applying a suite of culture 
conditions for even one factor, whether it is media, salinity, pH, temperature, etc., to 
every screened organism quickly becomes so labor and material intensive as to be 
impractical. The aim of this study, therefore, was to determine an ideal culture medium 
that could be applied to a drug discovery screening program as a standard preliminary 
medium. 
This ideal medium would have to fit several criteria. In a medium-throughput but 
academic setting, large volumes of media will be used, so only inexpensive, readily 
available, and easily prepared media were evaluated. In addition, some media that have 
shown promise as metabolite inducers in other studies, such as vermiculite,143 were 
excluded due to the high start-up cost necessary for such cultures. Our aim was to 
evaluate different media that could be integrated into the screening process with minimal 
changes to the existing equipment available. Six liquid broths and five solid-state media 
were chosen for evaluation. Three fungal strains were grown on each medium, and the 
resulting metabolite profiles were assessed. 
In addition to a qualitative examination of the metabolite profile, the production 
of several marker compounds was tracked. Each fungus chosen for this study was 
previously studied and characterized by our laboratory, and each produced a known 
compound sharing many structural features with compounds that our research group 
isolates. Two [Glomerella acutata (G2) and a Hypocreales sp. (G24)] were isolated as 
endophytes from pawpaw (Asimina triloba L., Annonaceae) leaves collected in North 
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America. The third strain, a Nectriacaea sp. (G142), was isolated from freshwater 
submerged wood collected in North America. All strains used belonged to Hypocreales, 
of the phylum Ascomycota.144 G2 and G142 both produced aurofusarin, while G24 
produced PC3. The goal was to identify two distinct fungi, one an endophyte and one 
from freshwater, that produced identical secondary metabolites, and two from the same 
source, endophytes from pawpaw, that biosynthesized distinct metabolites. The 
production of these metabolites was tracked to provide a more in-depth assessment of the 
fungal extracts.  
 
Materials and methods 
Isolation of fungi 
Study site, collection and isolation of fungal endophyte strains. Healthy living 
twigs and leaves of pawpaw (Asimina triloba L., Annonaceae) were randomly collected 
from a mature tree located at a private property in Indianapolis, Indiana, USA in July 
2011 (9012 Colgate St.). Extra moisture was removed from the samples, and they were 
transported back to the laboratory in paper bags, where they were processed within 24–48 
hours.145 In the lab, the twigs and leaves were cut into small pieces (approximately 2-5 
mm in length) and washed in distilled water (H2O).  Subsequently, the segments were 
surface-sterilized by sequential immersion in 95% ethyl alcohol (EtOH; 10 s), sodium 
hypochlorite (10-15% available chlorine; 2 min), and 70% EtOH (2 min).145 After the 
sterilization procedure, the plant segments were washed in distilled H2O and allowed to 
dry. The surface sterilized segments were then transferred using sterile conditions onto 
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2% malt extract agar [MEA; Difco, 20 g MEA, 1 L sterile distilled H2O amended with 
streptomycin sulfate (250 mg/L) and penicillin G (250 mg/L)]. To test the efficiency of 
the surface-sterilization procedure, and to confirm that emergent fungal colonies were 
indeed endophytic and not of epiphytic origin, individual surface-sterilized leaf and stem 
segments were spread on separate 2% MEA plates with antibiotics; the absence of fungal 
growth on the nutrient media confirmed the effectiveness of the sterilization procedure.146 
Plates were sealed with parafilm and incubated at room temperate in 12 h dark/light 
cycles until the emergence of fungal colonies was observed. Axenic cultures of emergent 
fungal endophytes are maintained at the University of North Carolina at Greensboro, 
Department of Chemistry and Biochemistry Fungal collection.  
 
Isolation of fungi from submerged wood in fresh water. Submerged, dead 
woody debris was collected randomly in a freshwater lake in North Carolina, USA in 
October 2011 (Lake Brandt, 36°10'1''N, 19°50' 18''W). Efforts were made to identify and 
collect substrates that had been submerged for a considerable time. This was estimated by 
observation of the degree of softening by fungal soft rot and colonization by other aquatic 
organisms. Samples were further processed in the laboratory to obtain axenic fungal 
cultures using established procedures.147, 148 Axenic cultures of freshwater fungi are 
maintained at the University of North Carolina at Greensboro, Department of Chemistry 
and Biochemistry Fungal collection.  
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Molecular identification of fungal strains by DNA extraction, PCR and 
sequencing. Methods employed to identify fungi isolated in this study using the nuclear 
ribosomal internal transcribed spacer region 1, 2, along with the short structural gene 
(5.8S) have been outlined in the supporting information of earlier studies.149-151 The ITS 
region was chosen to identify fungal species, as it has been recently identified as a 
barcode marker for fungi.152 Sequence data were deposited in GenBank; the accession 
numbers for G2, G24, and G142 were AB858344, AB858345, and AB858346, 
respectively. Cultures were deposited with the Leibniz Institute DSMZ-German 
Collection of Microorganisms and Cell Cultures; the accession numbers for G2, G24, and 
G142 were DSM 27861, DSM 27862, and DSM 27863, respectively. 
 
Liquid media cultivation 
Each fungal strain was first cultivated on 2% malt extract agar. Plugs from these 
cultures were used to inoculate 50 mL of six different culture broths in 250 mL 
Erlenmeyer flasks. These broths included Czapek Dox (CD)(Sigma Aldrich), 2% Malt 
Extract (ME)(Difco), Potato Dextrose (PD)(Difco), YPSS (4 g yeast extract, 14 g soluble 
starch, 1 g dibasic K2HPO4, 0.5 g MgSO4•7H2O, 1 L H2O), YESD (20 g soy peptone, 20 
g dextrose, 5 g yeast extract, 1 L H2O), and PYG (1.25 g soy peptone, 1.25 g yeast 
extract, 5 g D-glucose, 1 L H2O). Liquid cultures were grown for 14 days on an orbital 
shaker (100 rpm) at room temperature before extraction. Each culture was grown in 
triplicate. 
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Solid media cultivation 
Five forms of solid media, including rice, grits, oatmeal, wheat germ, and a 
3:1:1:1 mixture of the same were used. To prepare the solid media, 10 g of medium were 
mixed with 25 mL of deionized H2O in a 250 mL Erlenmeyer flask, sealed with a foam 
plug and tinfoil, and autoclaved. Plugs (from the 2% malt extract agar cultures listed 
above) of each fungus were used to inoculate 15 mL of YESD. These seed cultures were 
grown for three days on an orbital shaker (100 rpm) at room temperature, and these were 
used to inoculate the solid media, which was allowed to grow (stationary) for an 
additional 11 days at room temperature. Each culture was grown in triplicate. 
 
Extraction of fungal cultures 
To each culture, 60 mL of 1:1 chloroform:methanol (CHCl3:MeOH) were added. 
Solid media cultures were chopped with a spatula to ensure proper mixing. The cultures 
were shaken overnight (100 rpm) at room temperature and subsequently filtered by 
vacuum. The filtrate was stirred for 1 h with 90 mL of CHCl3 and 100 mL deionized H2O. 
This mixture was then transferred to a separatory funnel, and the bottom organic layer 
was evaporated to dryness in vacuo. The dried organic extract was reconstituted with 100 
mL 1:1 acetonitrile (CH3CN):MeOH and 100 mL hexanes. This biphasic solution was 
stirred for 1 h and transferred to a separatory funnel. The bottom, defatted organic extract 
was evaporated to dryness in vacuo.  
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Analysis of fungal metabolite profiles by ultra performance liquid chromatography-
mass spectrometry (UPLC-MS) 
The defatted organic extract of each fungal culture was examined by UPLC-MS. 
The method used was developed as part of a dereplication procedure.153 In brief, analyses 
were performed using a Waters Acquity UPLC system utilizing a BEH C18 column 
(Waters; 50 mm × 2.1 mm i.d., 1.8 µm). The mobile phase consisted of CH3CN and 0.1% 
formic acid-H2O, increasing linearly from 15% CH3CN at the time of injection to 100% 
CH3CN at 10 min. The flow rate was 0.3 mL/min and column temperature was 40 °C. 
The UPLC system was coupled to a Thermo Scientific LTQ Orbitrap XL equipped with 
electrospray ionization (ESI) source. The production of several known metabolites (Fig. 
7) was tracked using high-resolution mass spectrometry (HRMS). Crude extracts were 
dissolved in 1:1 MeOH:dioxane at a concentration of 2.0 mg/mL; 6.0 µL were injected, 
and the peak areas of each metabolite measured. Additionally, extracts were also 
examined using the same UPLC system equipped with an evaporative light scattering 
detector (ELSD; Waters); all other conditions were the same. 
 
 
Figure 7. Marker compounds used to track the production potential of various media; (7) 
aurofusarin, (8) PC3. 
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Results 
Effects of media on fungal growths 
The visual differences in fungal growth were the most immediately apparent 
result of varying the culture medium and were a primary instigator of this study; striking 
differences in color occurred as various secondary metabolites were stimulated by a new 
medium (Fig. 8). These color changes were most notable in liquid media, but the amount 
of sporulation (orange) and exudate (black) produced varied between solid media, too. As 
an example, after the 11 days of growth on solid media, the rice cultures of G2 exhibited 
almost no sporulation or exudate (Fig. 8), while the grits culture showed a small amount 
of black exudate, the oatmeal culture exhibited heavy sporulation (orange), and the wheat 
germ culture had a large amount of both.  
 
Effects of media on the profile of secondary metabolites 
The various media tested exhibited marked differences in the mass of extract 
(Figs. 9a and b). On the whole, the cultures grown on solid media produced extracts with 
masses one to two orders of magnitude larger than the same fungus grown in any of the 
liquid media. In both solid and liquid cultures, G2 consistently produced the lowest mass 
of extract, though this difference was more notable in the liquid media. The variation of 
the amount of extract produced was greater in liquid media than solid. The greatest 
variation between liquid media was shown by G24; in Czapek Dox broth, the culture 
produced less than two mg of total defatted extract, while it produced more than 20 mg 
when grown in potato dextrose broth and YESD broth (Fig. 9a).  
 
52 
 
 
Figure 8. Photos of G2 in liquid media (top); from left to right: Czapek dox, 2% malt extract, 
potato dextrose, YPSS, YESD, and PYG broths. Photos of G2 on solid media (bottom); from left 
to right: rice, grits, oatmeal, wheat germ, and 3:1:1:1, respectively, of the same. Enlargements of 
the photos (2.5x) are provided in the lower right hand corner to help visualize the production of 
spores (orange) and/or exudates (black). 
 
The mass of the defatted extract was also compared to the mass of the extract 
prior to the defatting step of the extraction procedure (Fig. 9c and d). Defatting is an 
important step in the extraction process for two reasons. The hexane wash eliminates 
some common but unwanted metabolites, such as fatty acids, that are not of interest to 
most natural product screening programs. It also cleans the extract of the very nonpolar 
constituents that are detrimental to reverse phase columns. Analyzing the percentage of 
extract lost in this defatting step can help to characterize the composition of the fungal 
extract.  
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Figure 9. A comparison of the (a) mass of defatted extract of fungal growths in liquid 
media, (b) mass of defatted extract of fungal growths on solid media, (c) percentage of 
organic extract retained after the defatting step (liquid media), and (d) the percentage of 
organic extract retained after the defatting step (solid media). Data plotted are means±SD 
of three replicate growths per culture medium. The “Negative” series in solid media (b 
and d) refers to the mass of extracted solid media alone, with no fungal growth. The same 
data for liquid cultures were negligible and therefore not shown. Abbreviations of media 
are defined in the Methods section. 
 
Extracts from solid media cultures retained a much smaller percentage of the 
original mass, typically between 10 and 30%, though G142 retained higher percentages 
of 42 and 52% on grits and the 3:1:1:1 mixture, respectively. Growths on liquid media, 
on the other hand, retained between 70 and 90% of their mass after the defatting wash, 
though all three fungi grown on Czapek Dox lost significant portions of their extract in 
this step.  
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Effects of media on composition of extract 
The UPLC profiles of the fungal extracts showed wide variation between media 
(Fig. S3, Appendix). Particularly in the liquid cultures, metabolites with vastly different 
retention times were produced. Grown in 2% malt extract broth (ME), G142 produced 
nine major peaks that eluted between 4 and 6.5 min on a 10-min CH3CN gradient. The 
same fungus grown in YPSS produced only five major peaks that all eluted after 7.5 min 
(Fig. S3, Appendix).  
The production of marker compounds (Fig. 7) was compared between media by 
measuring the peak areas of each metabolite via UPLC-MS and multiplying by total mass 
of the defatted extract, in order to more accurately compare the total production of each 
metabolite instead of the percentage of extract the metabolite comprised. This value was 
expressed as relative percentage of metabolite production, normalized to the largest value 
of each metabolite’s set. Aurofusarin was the metabolite of interest in both G2 and G142, 
while the metabolite of interest produced by G24 was PC3. Aurofusarin is a mycotoxin 
and red pigment common in Fusarium species.154-156  PC3 is an analog of pestalotin, 
which was first described as a product of an unidentified fungus in 1973;157 pestalotins 
synergistically augment the plant hormone gibberellin.158-160 While the structural 
diversity of compounds from fungi can be vast,161 these were chosen as representative 
compounds for a drug screening program, since they contain heteroatoms, conjugated 
rings, carbonyl groups, hydroxy, methoxy, and methyl moieties, and polyketide derived 
chains.  
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For all fungi, rice and grits consistently produced greater quantities of the marker 
compounds, while wheat germ consistently produced little or no marker compound. Few 
of the liquid cultures produced meaningful quantities of the marker compounds (Fig. 10), 
though they were detectable in most (Table 9). G2 produced modest amounts of 
aurofusarin when grown on oatmeal, when compared to the production when grown on 
rice; however, G142 consistently produced much greater quantities of aurofusarin on rice, 
grits, and oatmeal. While G2 produced little or no aurofusarin in the liquid cultures, G142 
produced quantities in ME and PD comparable to the production by G2 on several solid 
cultures (Fig. 10). PC3 production was highest when G24 was grown on rice and the 
3:1:1:1 mixture, though its production in CD, ME, and PD were similar to the production 
on solid media. 
 
 
Figure 10. Relative production of marker compounds aurofusarin in G2 and G142 (a), and PC3 in 
G24 (b). Data plotted are means±SD of three replicate growths per culture medium. 
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Table 9. Summary of the production of marker compounds in solid and liquid media 
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Aurofusarin (G2) m m m d m u d d d u u 
PC3 (G24) m m m d m m m m d u u 
Aurofusarin (G142) m m m m d d m m d d m 
Detection of marker compounds in solid and liquid media extracts; m = measured, as shown in bar graphs 
(Fig. 4), d = detected at low levels, u = undetected. Limit of detection 0.22 mg/g extract. 
 
  
Discussion 
It has been shown that media conditions have varying effects on the production of 
fungal secondary metabolites.132, 137 Often, the variation of culture conditions is used to 
optimize the yields of a specific compound, such as the active metabolite in a medicinal 
fungus134 or drug-producing microbe.162 In other cases, the OSMAC approach can be 
used to fully exploit the biodiversity of a small number of microbes, usually fewer than 
five.135, 163, 164 These techniques can be very valuable for manipulating the metabolomes 
of several fungi at a time, but they also increase the manpower necessary to process a 
single culture by several fold for each growth condition being manipulated. Our 
laboratory processes approximately 400 new fungal cultures every year; applying the 
OSMAC approach to each and every culture would be impractical without the 
implementation of specialized equipment and procedures for the parallel cultivation of 
screened fungi.133 
This study was designed to evaluate media with the intention of optimizing a 
drug-discovery screening program, which is a different goal than finding the ideal 
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medium for a specific microbial strain producing one or two key metabolites. What may 
be the best medium for one fungus could often prove unproductive for other strains. For 
example, G2 produced very little aurofusarin when grown on oatmeal, while G142 
produced quantities equivalent to its production on rice. In potato dextrose broth, G24 
and G142 produced large extracts, but the extract of G2 was less than 2 mg. Similarly, 
media that facilitate increased fungal growth and large amounts of extract may not 
produce compounds of interest. G24, when grown in PD or YESD liquid broths, 
produced extracts of similar masses to both each other and to its extracts when grown on 
rice, yet the metabolite of interest (PC3), was produced in significantly smaller quantities 
in PD and undetected in YESD. Thus, media in this study were evaluated with respect to 
both the amount of extract produced and the composition of that extract, including the 
production of the chosen marker compounds (Fig. 7). Because the media were being 
assessed for use in a screening program, consistency of production across all three fungal 
strains was a more important criterion than excellent production in just one of the strains. 
The variation in extract composition and marker compound production was more 
pronounced than expected when this study was designed. The most surprising outcome 
was that the marker compounds were undetected by UPLC-MS in several of the liquid 
culture extracts (Table 9). This was surprising, given that the limit of detection for the 
method was approximately 0.22 mg/g extract.153 Indeed, the amount of extract produced 
was often so drastically smaller than those produced by solid media cultures, that for a 
drug-discovery screening program, it would be impractical to use liquid cultures as a 
standard culture procedure; isolating sufficient quantities of compounds of interest would 
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be challenging. While it was enticing that the liquid cultures produced a lower percentage 
of fats than the solid media cultures, since fats complicate the purification process (Figs. 
9c and d), the overall paucity of metabolites negated this benefit.  
The production of marker compounds varied widely between all cultures. On 
oatmeal, G142 (isolated from freshwater) produced amounts of aurofusarin similar to 
cultures grown on rice; G2 (an endophyte) had very poor production on oatmeal. The use 
of only G142 in such a media survey would indicate that oatmeal may be an ideal 
candidate as a standard solid medium, while the added information provided by using the 
second fungus producing the same compound refuted this conclusion. A further example 
was the production of PC3 by G24 when grown on the 3:1:1:1 mixture. Again, while PC3 
was produced in quantities similar to that of the rice or grits media, G2 and G142 showed 
poor aurofusarin production on this same medium. In general, rice appeared to more 
consistently produce high quantities of the metabolites of interest, while wheat germ 
consistently did not.  
For the purposes of a fungal metabolite screening program, it seems clear that rice 
would serve well as a standard culture medium. The data supporting the use of rice as an 
ideal medium may not be surprising to researchers who routinely culture fungi; this study 
validates the empirical knowledge of many mycologists and natural products researchers 
who use rice as a go-to culture substrate. While liquid media did not perform well in this 
study, they should not be discounted as a viable culture condition in other circumstances. 
Different microbes, such as those found in marine environments, may be far more suited 
to a liquid growing environment than those cultured here. However, new metabolites 
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have been reported when marine fungi have been grown on rice,135 which supports the 
use of complex solid media as a standard culture condition.  
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CHAPTER VI 
EPIGENETIC MANIPULATION OF A FILAMENTOUS FUNGUS BY THE 
PROTEASOME-INHIBITOR BORTEZOMIB INDUCES THE PRODUCTION OF AN 
ADDITIONAL SECONDARY METABOLITE 
 
     This chapter is intended for publication in the journal RSC Advances and is presented  
     in that style. Coauthors include Blaise A. Darveaux, Wei-LunChen, Steven M.    
     Swanson, Cedric J. Pearce, Nicholas H. Oberlies. 
 
Introduction 
Fungal secondary metabolites are produced via several key pathways, including 
those involving polyketide synthases (PKSs), non-ribosomal peptide synthases (NRPSs), 
hybrid PKS-NRPS (HPN), as well as pathways coding for terpenes and indole 
alkaloids.105 In fungi, these genes are often found in clusters, a fact that has implications 
on the transcription and regulation of secondary metabolite pathways. With the recent 
completion of fungal genome sequences,106-109 it has become clear that the number of 
gene clusters encoding these pathways greatly outnumbers the known secondary 
metabolites for these organisms.110 A study on the sequence of Aspergillus niger 
demonstrated that less than 30% of its PKS-NRPS- and HPN-encoding gene clusters 
were transcriptionally active.111 This transcriptional suppression has led to a variety of 
studies delving into the mechanisms of transcriptional regulation, as well as developing 
techniques to induce these suppressed pathways. 
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Efforts have been made to manipulate the epigenetic regulation of gene 
transcription by growing fungi in the presence of various small-molecule modifiers. Such 
research has focused mainly on HDAC (histone deacetylase) inhibitors127-129, 165-168 and 
DNA methyltransferase (DNMT) inhibitors,129-131, 166-169 in order to make more 
transcriptionally available the genes that these proteins normally help to suppress. 
Treatment of A. alternata and Penicillium expansum with the HDAC inhibitor 
trichostatin A resulted in increased production of numerous secondary metabolites.127 A 
similar study using the HDAC inhibitor suberoylanilidehydroxamic acid (SAHA) to treat 
A. niger resulted in the isolation of a new metabolite, nygerone A, containing a unique 1-
phenylpyridin-4(1H)-one core that previously had not been reported from any natural 
source.128 Treatment of P. citreonigrum with the DNMT inhibitor 5-azacytidine (5-AZA) 
produced ten additional secondary metabolites, including two new compounds.130 New 
compounds have also been isolated from a SAHA-treated culture of Cladosporium 
cladosporioides and a 5-AZA-treated culture of a Diatrype species.129 The effects of 
SAHA and 5-AZA on A. nigerone expression were further characterized by using real-
time quantitative reverse-transcription PCR to analyze the change in expression of PKS, 
NRPS, and HPN pathways when treated with the epigenetic modifiers;166 all but seven of 
these 55 gene clusters showed increased transcriptional rates.  
This study examined the capability of bortezomib, a proteasome inhibitor, to 
induce the production of secondary metabolites in a fungus (MSX 63935, order 
Pleosporales) that had been shown previously to biosynthesize a series of resorcylic acid 
lactones of polyketide origin.170 Proteasomes are protein complexes responsible for the 
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degradation of proteins by proteolysis. Among the many proteins degraded by the 
proteasome pathway, several transcriptional regulators have been identified,140, 141 
implicating proteasomes as a crucial player in gene transcription. Growing MSX 63935 
in the presence of bortezomib induced the production of an additional secondary 
metabolite. An analogue was also isolated after degradation of the original metabolite in 
solution, yielding a new compound.  
 
Results and Discussion 
Preliminary experiments tested the effects of an HDAC inhibitor (SAHA), a 
DNMT inhibitor (5-AZA), and a proteasome inhibitor (bortezomib), on the secondary 
metabolite production of MSX 63935 in several growth media. Initial experiments with 
solid media (rice) showed poor results, regardless of very high doses of the epigenetic 
modifiers (as much as 100 mg per flask). Tests with liquid media, including CzapekDox 
broth and potato dextrose broth (PDB), were more promising. Increased production to the 
expected metabolites as well as a number of additional chromatographic peaks was 
observed in cultures dosed with epigenetic modifiers (Fig. 11). Secondary metabolite 
production was greater in PDB than CzapekDox (Fig. S4, Appendix), so subsequent 
experiments used PDB as the culture medium. Bortezomib was chosen for further 
experiments because the number of additional metabolites in preliminary experiments 
was greater when the fungus was grown with bortezomib than with SAHA (Fig. 11); 
while production by bortezomib-dosed cultures was similar to 5-AZA-dosed cultures, 
bortezomib had not been previously studied for this application. 
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Triplicate growths of the fungus in PDB containing 0, 25, 50, 75, 100, and 125 
µg/mL bortezomib were extracted and their organic extracts compared via gradient 
UPLC-ELSD. Relative levels of the resorcylic acid lactones170 and several fatty acids 
varied between replicate growths. In addition to those expected compounds, a new peak 
was evident in the chromatograms of the bortezomib-dosed growths (arrow, Fig. 12). 
Growths containing this peak were combined; the compound was isolated via preparative 
high pressure liquid chromatography (HPLC), and the structure analyzed. 
 
  
 
Figure 11. Comparison of control (A) and dosed (B-D) growths of MSX 63935 grown in potato 
dextrose broth. The culture shown in (B) was grown with 50 µg/mL SAHA, (C) with 100 µg/mL 
5-AZA, and (D) with 50 µg/mL bortezomib. The separation was performed via UPLC-PDA (235 
nm), using a C18 column and a gradient increasing linearly from 10% CH3CN (H2O) at 0.0 min to 
100% at 4.5 min, held at 100% for an additional 0.5 min. All extracts were solubilized at 0.2 
mg/mL and injected at a volume of 6 µL. 
 
 
A
B
C
D
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Figure 12. Comparison of control (A) and dosed (B) growths of MSX 63935, grown in potato 
dextrose broth with 75 µg/mL bortezomib. The arrow indicates a peak that does not appear in 
extracts of control growths. The peaks in (B) after 4.5 minutes were attributed to fatty acids. The 
separation was performed via UPLC-ELSD, using a C18 column and a gradient increasing linearly 
from 10% CH3CN (H2O) at 0.0 min to 100% at 4.5 min, held at 100% for an additional 0.5 min.  
 
Compound 9 (Fig. 13, Table 10) was obtained as a white powder. Using 
HRESIMS, a molecular ion was measured at 307.1165 [M+H]+ (calcd for C16H19O6, 
307.1176), indicating a molecular formula of C16H18O6 with eight degrees of 
unsaturation. The 1H NMR spectrum displayed two aromatic m-coupled protons at δH 
7.20 (H-6) and δH 7.22 (H-8), a singlet at δH 6.28 (H-3), a methoxy signal at δH 3.96, and 
signals for six protons corresponding to the hydroxylated aliphatic side chain at δH 4.06 
(H-2′), 2.88 and 2.70 (H-1′a/b), 1.56 (H-3′), 1.56 and 1.45 (H-4′), and 0.98 (H-5′). The 
structure of this side chain was assigned based on examination of COSY data (Fig. 14). 
HMBC correlations (Fig. 14) between H-3 and carbons C-2 (δ 167.0) and C-1′ (δC 43.3), 
A
B
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as well as between the diastereotopic H-1′ protons and the C-2 and C-3 (δC 112.0) 
carbons, determined the C-2/C-1′ bond. Further analysis of the HMBC and HSQC data 
and a search of the literature suggested the chromone skeleton, which accounted for 
seven degrees of unsaturation.171-173 An HMBC correlation between the methoxy singlet 
and the C-7 carbon (δC 165.4) established its connectivity to the aromatic ring. The mass 
indicated a carboxylic acid moiety as the remaining substituent, accounting for the last 
degree of unsaturation; this was corroborated by a correlation between the H-6 proton 
and the carboxylic acid carbon (δC 171.9). A four-bond correlation between the H-3 
proton and C-5 (δC 136.8), established the position of the carboxylic acid moiety. The 
absolute configuration was assigned using a modified Mosher’s ester analysis (Fig. 
15).174  
 
 
 
Figure 13. Compound 9 was isolated from bortezomib-dosed growths of MSX 63935, and 10 was 
isolated from a degraded solution of 9.  
 
 
 
 
Figure 14. Key HMBC ( ) and COSY ( ) correlations of compound 9.  
 
 
 
6
8
8a
4a
O
HO O
3
O
O
2
1'
2'
3'
4' 5'
OH
1
O
HO O
O
O
2
 
O
HO O
O
O
OH
 
66 
 
 
Figure 15. ΔδH values [Δδ(in ppm) = δS – δR] obtained for (R)- and (S)-MTPA esters (9a and 9b, 
respectively) in pyridine-d5. 
 
A compound with the same planar structure as 9 was isolated from the plant 
Stratiotes aloides in 2009.172 Those authors did not assign the absolute configuration, 
possibly due to paucity of material (less than 200 µg).172 Due to signal overlap of the 
DMSO-d6 solvent, the data reported here were obtained in MeOH-d4, though 1H and 13C 
NMR spectra were also acquired in DMSO-d6. Key differences between NMR signals in 
DMSO-d6 were noted at positions H-3, H-6, H-8, and C-5 (Table S3, Appendix). 
However, both the NMR data and the UV maxima175 at 233 and 291 supporedt the 
chromone skeleton, and the structure of the alkyl side chain was firmly assigned by 2D 
NMR. Coupling of the H-6 and H-8 protons (J = 2.3) established the meta positions of 
the aromatic protons, and the strong four-bond H-3 to C-5 correlation confirmed the 
position of the carboxylic acid. 
 
O
HO O
-0.17
O
O -0.01
+0.06
+0.15
+0.07
OR
9a: R = (R)-MTPA
9b: R = (S)-MTPA
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Table 10. NMR Data (400 MHz, MeOH-d4) of compounds 9 and 10. 
10 
HMBCa 
 
2, 4, 4a, 5, 1' 
 
 
 
4a, 8, 5-COOH 
 
4a, 7, 8a 
 
2, 3' 
 
2, 3', 4' 
1', 2', 4', 5' 
2', 3', 5' 
3', 4' 
7 
 
aHMBC correlations are from the proton(s) listed to the indicated carbons. 
bOverlapping signals 
cThe quaternary 13C signals for C-4, C-5, and 5-COOH werevery weak, and their δC values were corroborated by HMBC data. 
 
δC, type 
161.8, C 
107.3, CH 
177.6, Cc 
112.9, C 
138.5, Cc 
100.8, CH 
163.4, C 
114.0, CH 
157.9, C 
121.5, CH 
 
141.8, CH 
034.0, CH2 
020.9, CH2 
012.1, CH3 
054.9, CH3 
171.5, Cc 
δH, mult. (J in Hz) 
 
6.21, s 
 
 
 
7.13, d (2.3) 
 
7.20, d (2.3) 
 
6.33, dd (1.4, 15.6) 
 
6.98, dt (7.3, 15.6) 
2.31, ddt (1.4, 7.3, 
 1.58, sextet (7.3) 
1.00, t (7.3) 
3.95, s 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9 
HMBCa 
 
2, 4, 4a, 5, 1' 
 
 
 
4a, 8, 5-COOH 
 
4a, 6, 7, 8a 
 
2, 3, 2', 3' 
2, 3, 2', 3' 
 
1', 2', 4', 5' 
2', 3', 5' 
3', 4' 
7 
 
δC, type 
167.0, C 
112.0, CH 
179.4, C 
114.9, C 
136.8, C 
103.3, CH 
165.4, C 
116.8, CH 
160.6, C 
043.3, CH2 
 
070.0, CH 
040.8, CH2 
020.1, CH2 
014.5, CH3 
057.1, CH3 
171.9, C 
δH, mult. (J in Hz) 
 
6.28, s 
 
 
 
7.20, d (2.3) 
 
7.22, d (2.3) 
 
2.88, dd (4.1, 14.7) 
2.70, dd (9.2, 14.7) 
4.06, m 
1.56, mb 
1.56, mb / 1.45, m 
0.98, t (6.9) 
3.96, s 
 
 
position 
2 
3 
4 
4a 
5 
6 
7 
8 
8a 
1a' 
1b' 
2' 
3' 
4' 
5' 
7-OCH3 
5-COOH 
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During an unsuccessful attempt to crystalize 9, the molecule degraded in solution, 
yielding several analogues, one in quantities sufficient to assign a structure. Compound 
10 (Fig. 13), which was new, represented the dehydro analogue of 9, which was 
supported by an 18 amu difference in the HRMS data and an increase by one in the index 
of hydrogen deficiency. COSY data, especially a correlation between H-2′ (δH 6.98) and 
H-3′ (δH 2.31), helped assign the alkene side chain. The large vicinal coupling constant 
between H-2′ and H-3′ (J = 15.1) established the trans configuration.  
Both 9 and 10 were tested for cytotoxicity against human melanoma and colon 
cancer cells and were found to be inactive (i.e., IC50 values > 20 µM). 
To our knowledge, this is the first use of a proteasome inhibitor in epigenetic 
modification studies to induce additional secondary metabolites from microorganisms, 
and may inspire new methods for the up-regulation of silent metabolite genes. 
 
Experimental Section 
Culture Methods 
Mycosynthetix fungal strain 63935 was isolated in 1992 by Dr. Barry Katz of 
MYCOsearch from leaf litter. The culture was stored on a malt extract slant and was 
transferred periodically. A fresh culture was grown on malt extract agar in a 10 cm 
diameter Petri plate at 22 °C for 20 d, until the cultures were approximately 2.5 cm in 
diameter. The cultures were cut into small squares, which were used to inoculate 250-mL 
Erlenmeyer flasks containing 50 mL of potato dextrose broth (PDB). At the time of 
inoculation, 0.5 mL aliquots of DMSO-dissolved bortezomib was added in triplicate to 15 
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flasks, resulting in final concentrations in the liquid media of 25, 50, 75, 100, and 125 
µg/mL bortezomib. Three flasks were treated with 0.5 mL DMSO (vehicle control), and 
three flasks were untreated (negative control). The cultures were grown with shaking 
(100 rpm) at 22 °C for 14 d. 
 
Extraction and Isolation 
The cultures were shaken overnight with 60 mL of 1:1 CHCl3:MeOH and filtered 
the next day. To the filtrate was added 90 mL of CHCl3 and 100 mL of deionized H2O to 
produce a 4:1:5 mixture of CHCl3:MeOH:H2O (including the 50 mL of H2O from the 
liquid media). This mixture was stirred for 1 h, then transferred to a separatory funnel.  
The organic portions were dried in vacuo, then shaken with a 1:1:2 mixture of 
CH3CN:MeOH:hexanes. The CH3CN:MeOH layers were separated, and all extracts were 
dried in vacuo, transferred to scintillation vials, then dried completely under air. The 
extracts of the cultures exhibiting the presence of the new metabolite (Fig. 2) were 
combined (90.85 mg) and subjected to preparative C18 HPLC using an isocratic 40:60 
CH3CN:H2O method over 25 min, followed by a 100% CH3CN column wash (10 min). 
Compound 1 eluted at ~14 min (6.32 mg).  
 
Instrumentation 
Optical rotation was measured with a Rudolph Autopol III polarimeter; UV 
spectra were obtained using a Varian Cary 3 UV-vis spectrophotometer. NMR 
experiments were performed on a JEOL ECS 400 MHz NMR equipped with a high 
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sensitivity JEOL Royal probe and an autosampler. Selected samples were measured using 
a Bruker Avance-III 600 MHz NMR. HRESIMS data were acquired using a Thermo 
LTQ Orbitrap XL mass spectrometer equipped with an electrospray ionization source. 
UPLC was performed using a Waters Aquity system, equipped with a photodiode array 
detector (PDA) and evaporative light scattering detector (ELSD) with data collected and 
analyzed using Empower software. A Waters BEH C18 column (1.7 µm; 50 × 2.1 mm) 
was used with a 0.6 mL/min flow rate. Preparative HPLC was performed using a Varian 
Prostar HPLC system equipped with ProStar 210 pumps and a Prostar 335 PDA, with 
data collected and analyzed using Galaxie Chromatography Workstation software 
(version 1.9.3.2). A YMC ODS-A C18 column (5 µm; 250 × 20 mm) was used with a 
9.45 mL/min flow rate. 
 
(R)-2-(2-hydroxypentyl)-5-carboxy-7-methoxychromone (9)  
White powder; [α]20D −26 (c 0.179, MeOH);  UV(MeOH) λmax (log ε) 233 (3.01), 
291 (2.85); 1H NMR (400 MHz, MeOD-d4) see Table 10; 13C NMR (400 MHz, MeOD) 
see Table 10; HRESIMS m/z 307.1165 (calcd for C16H19O6, 307.1176) [M+H]+.   
 
(E)-2-(pent-1-en-1-yl)-5-carboxy-7-methoxychromone (10) 
White powder; UV(MeOH) λmax (log ε) 256 (3.28), 317 (3.31); 1H NMR (400 
MHz, MeOD-d4) see Table 10; 13C NMR (400 MHz, MeOD) see Table 10; HRESIMS 
m/z 289.1069 (calcd for C16H17O5, 289.1071) [M+H]+.   
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Preparation of (R)- and (S)-MTPA ester derivatives of (9)  
To 1.00 mg of compound 9, 1000 µL of pyridine-d5 were added; from this, 500 
µL were transferred to two separate NMR tubes. To initiate the reaction, 10 µL of S-(+)-
α-methoxy-α-(trifluoromethyl)phenylacetyl (MTPA) chloride were added to one NMR 
tube and shaken. The reaction was monitored immediately by 1H NMR at the following 
time points: 0, 15, and 30 min. At 30 min, an additional 10 µL of S-MTPA chloride were 
added and the tube shaken. The reaction was monitored further at 40, 45, and 55 min, at 
which point it was determined to be complete, yielding the mono (R)-MTPA ester 
derivative (9a) of 9. To the second NMR tube was added 20 µL of the (R)-MTPA 
chloride; the reaction was shaken, then monitored immediately by 1H NMR at the 
following time points: 0, 15, 30, and 40 min. The reaction was found to be complete 
within 40 min, yielding the mono (S)-MTPA ester derivative (9b) of 9. 1H NMR (500 
MHz, pyridine-d5) of 9a: δH 0.80 (3H, t, H-5′), 1.28 (2H, m, H-4′), 1.71 (2H, m, H-3′), 
3.14 (2H, m, H-1′), 5.78 (1H, m, H-2′), 6.62 (1H, s, H-3). The signals from H-6, H-8, and 
the methoxy group were obscured by solvent and reagent peaks. 1H NMR (500 MHz, 
pyridine-d5) of 9b: δH 0.87 (3H, t, H-5′), 1.43 (2H, m, H-4′), 1.77 (2H, m, H-3′), 5.77 (1H, 
m, H-2′), 6.45 (1H, s, H-3). The signals from H-1′, H-6, H-8, and the methoxy group 
were obscured by solvent and reagent peaks. 
 
Cytotoxicity Assays 
Human melanoma cancer cells designated MDA-MB-435 and human colon 
cancers designated HT-29 were purchased from the American Type Culture Collection 
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(Manassas, VA). The cell lines were propagated at 37°C in 5% CO2 in RPMI 1640 
medium supplemented with fetal bovine serum (10%), penicillin (100 units/mL), and 
streptomycin (100 µg/mL). Cells in log phase growth were harvested by trypsinization 
followed by two washing to remove all traces of enzyme. A total of 5,000 cells were 
seeded per well of a 96-well clear, flat-bottom plate and incubated overnight (37°C in 5% 
CO2). Samples dissolved in DMSO were then diluted and added to the appropriate wells 
(concentrations: 20, 4, 0.8, 0.16, and 0.032 µM; total volume: 100 µL; DMSO: 0.5%). 
The cells were incubated in the presence of test substance for 72 h at 37°C and evaluated 
for viability with a commercial absorbance assay (CellTiter 96® AQueous One Solution 
Cell Proliferation Assay, Promega Corp, Madison, WI) that measured viable cells. IC50 
values were expressed by µM relative to the solvent (DMSO) control. The positive 
control was vinblastine tested at 1 nM in MDA-MB-435 cells, yielding 16% viable cells 
or 10 nM in HT-29 cells, which yielded 39% viable cells. 
 
Acknowledgement 
 This research was supported by program project Grant P01 CA125066 from 
the National Cancer Institute/National Institutes of Health, Bethesda, MD, USA. Selected 
NMR data were obtained by Dr. Kevin Knagge at the David H. Murdock Research 
Institute Kannapolis. 
 
 
73 
CHAPTER VII 
ROMIDEPSIN (ISTODAX®, NSC 630176, FR901228, FK228, DEPSIPEPTIDE): A 
NATURAL PRODUCT RECENTLY APPROVED FOR CUTANEOUS T-CELL 
LYMPHOMA 
 
     This chapter has been published in the Journal of Antibiotics and is presented in that     
     style. VanderMolen, K.M., McCulloch, W., Pearce, C.J. and Oberlies, N.H. J. Antibiot. 2011.  
     64, 525-531. 
 
Romidepsin, a histone deacetylase inhibitor with a unique chemical structure, was 
approved for the treatment of cutaneous T-cell lymphoma in November 2009 by the US 
FDA. It was discovered from cultures of Chromobacterium violaceum, a bacterium 
isolated from a Japanese soil sample. This bicyclic compound acts as a prodrug, its 
disulfide bridge being reduced by glutathione upon uptake into the cell, allowing the 
sulfhydryls to interact with Zn ions in the active site of class I and II histone deacetylase 
enzymes. Due to the synthetic complexity of the compound, as well as the low yield from 
the producing organism, analogs are sought to create synthetically accessible alternatives. 
As a T-cell lymphoma drug, romidepsin offers a valuable new treatment for diseases with 
few effective therapies.  
 
Introduction to HDAC Inhibitors 
Alteration of gene expression due to epigenetic modification of the chromatin 
structure has been implicated as an important factor in tumorigenesis.122, 176 In chromatin, 
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DNA is tightly coiled around core histone proteins, forming nucleosomes; linker histones 
bind nucleosomes together as chromatin. Methylation, acetylation, phosphorylation, 
ADP-ribosylation, or ubiquitination of the histone tail regions affect the binding of the 
histone proteins to DNA, changing the structure of the chromatin and subsequently the 
accessibility of transcription factors to DNA regions.120 Such epigenetic processes alter 
levels of gene expression without changing the nucleotide sequence.177 Of these 
modifications, histone acetylation is the most widely studied due to its role in the 
development and progression of tumors.122  
Histone acetylation is controlled by the enzymes histone acetyltransferases 
(HATs) and histone deacetylases (HDACs). HATs direct the addition of acetyl groups to 
lysine residues in the amino-terminal histone tails, neutralizing that portion of the protein 
and relaxing the chromatin structure, thereby increasing accessibility of transcription 
complexes as well as recruiting transcription cofactors.120-123 Conversely, HDACs 
remove acetyl groups from the histone tails, resulting in a more compact and inaccessible 
form of chromatin, consequently silencing transcription.120-122 These effects are highly 
localized, and only 2-5% of encoding genes are transcriptionally regulated by the histone 
acetylation state.122 Importantly, this selection includes genes that control the cell cycle 
and apoptosis, and HDACs have been associated with several well characterized 
oncogenes and tumor suppressor genes.178, 179 Certain tumors have overexpressed HDACs 
and downregulated or mutated HATs.180 It has been suggested that an imbalance of 
HDAC relative to HAT activity can lead to a diminished expression of such regulatory 
genes and ensuing tumorigenesis.180 
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HDAC inhibitors have been found to have therapeutic properties in many 
different tumor cell lines, including human cancer cell lines derived from the bladder, 
breast, prostate, lung, ovary, colon, among others,181 indicating that the inhibition of 
HDAC activity may be a viable strategy for the treatment of cancers.182-184 It is also likely 
that HDAC inhibitors affect a number of subcellular pathways, and time will tell what 
impact these other mechanisms have on treatment of cancer and/or other diseases. HDAC 
inhibitors can be divided into four classes, namely hydroximates, cyclic peptides, 
aliphatic acids, and benzamides.185 A new HDAC inhibitor, romidepsin, which has been 
referred to by several different names in the literature, including FK228, FR 901228, 
NSC 630176, depsipeptide, and Istodax®, is a pentapeptide isolated from cultures of 
Chromobacterium violaceum.186 The structure (Fig. 16, 11) is composed of four amino 
acids (D-valine, D-cysteine, Z-dehydrobutyrine, L-valine) and (3S,4E)-3-hydroxy-7-
mercapto-4-heptenoic acid, arranged as a bicyclic depsipeptide. The numbering of 11 is 
based on Xiao et al.187, 188Romidepsin was approved by the U.S. FDA in 2009 for use in 
patients with cutaneous T-cell lymphoma (CTCL). 
 
Background on Cutaneous T-Cell Lymphoma 
The incidence of CTCL in the general population is estimated to be 1-4/100 
000,189, 190 with approximately 1500 new cases and 500 deaths per year in the United 
States (US).191 CTCL is twice as prevalent in males as in females, and the median age of 
presentation is 57 years. In the US, the disease is also more common among African-
Americans than in other race categories.190 Approximately 16 000 to 20 000 individuals 
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in the US are affected by CTCL.191 One study from 1973 to 1984192 found a 3.2-fold 
increase in the incidence of CTCL over that time period; a similar study from 1973 to 
2002193 reported a 3.4-fold increase in incidence over the course of the study.  
 
 
Figure 16. Structures of romidepsin (11) and the reduced counterpart (12).188 
 
The most common types of CTCL are mycosis fungoides (MF), so called because 
early physicians believed it to be a fungal infection although it is not, and the Sézary 
syndrome. Sézary syndrome, the leukemic variant, is characterized by pruritus, 
generalized exfoliative erythroderma, and abnormal lymphoid cells in the blood. The 
blood is usually not affected in MF, especially in the early stages. Skin lesions are 
characterized as patches, plaques, or tumors that have a “bathing trunk” distribution.  The 
lymphoma may extend to cover a large surface area, lymph nodes, and, in later stages, 
viscera.   
MF is the most common type of CTCL, and is characterized by pink or 
erythematous scaly patches and plaques, with varying degrees of scaling and pruritus.194  
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At the time of diagnosis, the majority of patients with MF have limited plaques on ≤10% 
of their total body surface.  However, approximately one-third (30%) have extensive 
plaques.  Relatively small proportions of patients present with cutaneous tumors (16%) or 
generalized erythroderma (12%).  Non-skin lesions are more likely to be seen in later 
stage disease, with 8% seen in stage T2, 30% in stage T3, and 42% in stage T4. The 
primary non-skin and non-lymph node sites are lung, gastrointestinal (GI), liver, and 
central nervous system (CNS). Bone marrow (BM) involvement is rare in early stage 
disease.   
CTCL is uniformly fatal.  The ultimate cause of death for patients with CTCL is 
commonly infection, particularly sepsis, from Pseudomonas aeruginosa or 
Staphylococcus aureus, caused by chronic skin infection and subsequent systemic 
infections.195 Prognosis is dependent on age as well as disease stage at diagnosis,196 with 
earlier stage disease associated with higher 5-year overall survival and disease-free 
survival rates than later stage disease. The overall 5-year survival rate for patients with 
mycosis fungoides (MF) is 91%, while it is only 40% for those with Sézary syndrome 
(SS).197 Typically, those presenting with early stages of CTCL have a favorable 
prognosis, with around 95% 5-year survival;196, 198, 199 more advanced stages have lower 
survival rates ranging from 30% to 84%,196, 198, 199 again depending on form and stage of 
the cancer. According to one study, the 10-year survival rate drops from around 100% for 
those with stage T1 CTCL to 67% for T2; by stage T3, this number drops to 40%.200 
While most patients present with the early-stage disease, approximately 10-20% of these 
will progress to a later and often fatal disease.196, 198, 201 Patients that undergo 
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transformation to large-cell lymphoma have a mean survival ranging from 2 to 19 
months.201 
 
Discovery and Early Development of Romidepsin 
Romidepsin was discovered in 1993 through a program that was evaluating 
fermentation products for antimicrobial and antitumor activities. The producing 
organism, Chromobacterium violaceum, is a Gram-negative, rod-shaped bacterium with a 
single polar flagellum. The strain was isolated from a soil sample collected in the 
Yamagata-prefecture in Japan.186 Presently, the commercial supply of romidepsin is 
generated via fermentation, although the yield and exact conditions are proprietary.  
C. violaceum was cultured in nutrient broth with additional glucose and incubated 
at 30°C aerobically and with agitation. The organism reached stationary phase after 72 h, 
providing a maximal yield of romidepsin at this time of 19 μg/mL, which was present in 
the aqueous part of the culture. The fermentation was filtered, and the filtrate extracted 
twice with EtOAc. The extract was evaporated in vacuo to give an oily residue, which 
was then purified via normal phase chromatography to yield a yellow powder.  
This powder was dissolved in CH2Cl2:CH3OH:CH3CN (10:1:20), and romidepsin 
crystallized as colorless prisms. It displayed weak antifungal but no antibacterial activity, 
but it showed potent cytotoxicity against several human lung carcinoma cell lines, as well 
as human stomach, breast, and colon adenocarcinoma cell lines.186 The structure of 11, 
which is a cage-shaped bicyclic depsipeptide, was determined using a combination of 
spectroscopic techniques, primarily NMR and x-ray crystallography.202  
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Romidepsin demonstrated the ability to reverse the effects of the ras oncogene in 
vitro, which has been shown to play a role in tumor development; expression of the Ha-
ras oncogene appears to be directly correlated with tumorigenic potential.203 Because of 
romidepsin’s ability to reverse the ras-transformed phenotype to normal, as well as its 
cytotoxic effects, it was developed initially by the US National Cancer Institute as an 
anti-ras compound,204, 205 but recently it has been shown to be an HDAC inhibitor.206, 207 
A program screening a number of known microbial metabolites for transcriptional 
activation of the SV40 promoter identified romidepsin as an antitumor compound.206 
Comparison of its activity to that of TSA revealed that romidepsin was a new HDAC 
inhibitor.206 
 
Mechanisms of Action 
Romidepsin is converted in cells to its active form by the reduction of the 
disulfide bond by glutathione, resulting in a monocyclic dithiol (12),187, 208 and thus 
romidepsin serves as a prodrug that is activated only after uptake into cells. This reduced 
form (2) is inactivated rapidly in serum, perhaps due to sequestration by serum 
proteins.208 A cysteine in the active site pocket (Cys-151 in HDAC1) was thought to 
covalently bind with the reduced sulfur atom at position 13, but a mutant HDAC1 in 
which this cysteine was replaced by a serine was still sensitive to romidepsin, though a 
higher concentration (~8×) of the drug was necessary for inhibition.208 This fact, 
combined with the reversibility of the inhibition, suggests that while the cysteine may 
play a role in the affinity of the drug, it most likely does not bind covalently to the sulfur 
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atom.208 Crystallographic and computer modeling studies using a HDAC-trichostatin A 
complex suggested that one of the sulfhydryl groups of the reduced depsipeptide interacts 
with zinc ions in the active site pocket of certain enzymes, preventing access of the 
substrate.209 A computer modeling study by Furumai et al.208 concluded that when 
interacting with HDAC1 the sulfur atom of the reduced romidepsin was located at a 
position that allowed interaction with the zinc ion via a water molecule. They also 
suggested that, based on a similar mechanism in protease inhibitors, the sulfur may 
tetrahedrally coordinate with the zinc, displacing the water molecule.208 The interaction 
between the sulfhydryl group and the active site of the enzyme prevents other substrates 
from binding. 
The reduced form more strongly inhibits HDAC1 and HDAC2 enzymes (class I) 
than HDAC4 and HDAC6 enzymes (class II).208 By inhibiting HDAC Class I enzymes, 
romidepsin inhibits the removal of acetyl groups from the lysine residues of N-terminal 
histone tails, maintaining a more open and transcriptionally active chromatin state.121  
Romidepsin also results in altered acetylation of other nuclear and cytoplasmic 
proteins, though the precise pathways by which it affects the cell cycle, apoptosis, and 
angiogenesis have not been defined completely.210 
 
Cell Cycle Arrest 
The induction of growth arrest and/or apoptosis by romidepsin depends on the cell 
line tested and the concentration of drug applied.210 Growth arrest, as opposed to 
apoptosis, is the predominant response in cell lines in which the application of 
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romidepsin induces the expression of the p21 tumor-suppressor gene.211 Cell lines with 
reduced p21 expression preferentially undergo apoptosis.212 Tumor cells are more 
susceptible to romidepsin than normal cells,186 a fact that leads to a viable therapeutic 
index in the clinic.  
Direct acetylation of non-histone proteins may also trigger growth arrest or 
apoptosis, and several pathways have been studied, though the complete role of HDAC 
inhibitors is not fully understood. Exposure of whole cells to romidepsin results in a 
decrease of cyclin D1 and c-myc, accompanied by an increase in p53-independent p21 
WAF1/Cip 1 induction. The p21 induction leads to inhibition of cyclin-dependent kinase 
(CDK) and dephosphorylation of the retinoblastoma protein (Rb), which results in early 
G1 phase cell cycle arrest.213, 214 A different mechanism involves altered expression of 
cyclin A and D, and p27/Kip1, again resulting in reduced CDK activity and cell cycle 
arrest.214 
 
Apoptosis 
There are two mechanisms leading to apoptosis: the death receptor pathway and 
the intrinsic pathway.215 While exposure to romidepsin and other HDAC inhibitors can 
lead to hyper-acetylation of death receptor promoters, including TRAIL (tumor-necrosis 
factor-related apoptosis-inducing ligand), death receptor 5, Fas ligand and Fas,216 the 
significance of this mechanism does not seem to be universally acknowledged. Some 
leukemia cells do not show induction of the TRAIL or Fas pathways, or undergo 
apoptosis after exposure to HDAC inhibitors.217 The intrinsic pathway involves the 
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perturbation of mictochondrial membranes resulting in the generation of reactive oxygen 
species (ROS). In normal cells exposed to HDAC inhibitors, ROS do not accumulate due 
to breakdown by thioredoxin; some tumor cells that do not express the thioredoxin gene 
accumulate ROS and undergo apoptosis. 215  
Romidepsin has also been shown to increase acetylation of the HSP 90 chaperone 
protein, causing proteasomal degradation and inducing apoptosis.218 The proteasome 
inhibitor bortezomib appears to work synergistically with HDAC inhibitors,219 but it is 
interesting that the HSP 90 inhibitor, geldanamycin, antagonizes HDAC inhibitor 
activity.220  
 
Angiogenesis Inhibition 
Romidepsin inhibits hypoxia-induced angiogenesis of endothelieal cells in vitro, 
but does not cause cytotoxicity. It decreased angiogenesis in a chick embryo model, with 
no signs of thrombosis or hemorrhage, and inhibited angiogenesis strongly in mouse 
model tumors.221  Romidepsin appears to reduce angiogenic-stimulating factors such as 
VEGFs, VEGF receptor, FLT1 and FLK1, and increases induction of angiogenic 
inhibitory factors VHL and neurofibromin2,221 however, the correlation between anti-
VEGF activity and in vivo efficacy has not been established.  
Pharmacology 
Pharmacokinetics  
A two-compartment model with linear kinetics can be used in the 
pharmacokinetic analysis of romidepsin.222, 223 Two dosing schedules were studied in 
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separate Phase I trials. One schedule involved a 4-h infusion on days 1 and 5 of a 21-day 
cycle, where the MTD (maximum tolerated dose) was determined as 17.8 mg/m2,223 
while the second involved a 4-h infusion on days 1, 8, and 15 of a 28-day cycle, where 
the MTD was determined as 13.3 mg/m2.224 With both schedules, romidepsin exhibited 
linear pharmacokinetics up to the MTD.223, 224  Total clearance volumes in adults have 
been reported as 4.8 L/h/m2 at a 13 mg/m2 dose,225 and 10.5 L/h/m2 at a 17.8 mg/m2 
dose.223 A Phase I study in pediatric patients (2-21 years, median age 13) with refractory 
solid tumors who received romidepsin in 4-h infusions of 17 mg/m2 reported a clearance 
volume of 6.8 L/h/m2.226 The elimination half-life has been reported as 3.5 h222 and 3.67 
h225 at 13 mg/m2, and 8.1 h223 at 17.8 mg/m2.  
 
Pharmacodynamics 
A typical assay for pharmacodynamic studies is to monitor histone acetylation of 
peripheral blood mononuclear cells (PBMCs).223, 226, 227 Increased acetylation is observed 
in patients’ PBMCs after treatment with romidepsin, with maximal accumulation of 
acetyl H3 histones in PBMCs occurring at 4 h after the end of an infusion.226A study in 
patients with acute myelogenous leukemia and chronic lymphocytic leukemia (CLL) 
using a 4 h 13mg/m2 infusion on days 1, 8, and 15 of a 28-day cycle reported 100% 
histone acetylation of H3 and H4 histones for all CLL patients after 4 h, and for 6 out of 7 
CLL patients after 24 h.225 This study also reported an increase in p21 protein expression 
concurrent with H4 acetylation of the p21 promoter gene.225  
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A Phase II study of T-cell lymphoma patients monitored several biomarkers: 
PBMC histone acetylation, ABCB1 gene expression in PBMCs, ABCB1 gene expression 
in biopsy samples, and blood fetal hemoglobin (HbF) levels.228 A global increase in 
PBMC histone acetylation was reported in 73% of patients within 4 h of treatment, and in 
40% of patients after 24 to 48 h.228 The number of patients having a twofold or higher 
than baseline ABCB1 expression in PBMCs was 56% at 4 h, and 30% at 48 h.228 A 
fourfold or greater increase in circulating HbF was reported in 60% of the patients. The 
histone H3 acetylation in PBMCs at the 24-h time point appeared to correlate with 
response; there was no correlation between the levels of ABCB1 induction and 
pharmacokinetic parameters, or between ABCB1 induction in biopsy samples and clinical 
disease reponse.228 These data suggested that peak drug concentration (Cmax) and overall 
exposure were important in determining response.228, 229 
 
T-Cell Lymphoma Clinical Trials 
In preclinical studies, greater antitumor activity was observed with intermittent 
administration than with daily administration.223 Short infusions (>30 s to 4 min) and 
prolonged infusions (>24 h) caused greater toxicity than infusions of 1-4 h.223 Therefore, 
in Phase I trials, romidepsin was tested using a 4-h intravenous infusion. Patients who 
consent to be treated in Phase I trials have cancers for which no known standard therapy 
exists, or such therapy has already failed, so that patients are not denied any curative or 
definitely life-extending options. One Phase I study223 administered a 4-h infusion on 
days 1 and 5 of a 21-day cycle; the MTD was defined at 17.8 mg/m2 with dose-limiting 
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toxicity (DLT) manifest as grade-3 fatigue, grade-3 nausea and vomiting, grade-4 
thrombocytopenia (low platelet levels), and grade-4 cardiac arrhythmia. Another Phase I 
study224 administered romidepsin in a 4-h infusion on days 1, 8, and 15 of a 28-day cycle; 
the MTD in this trial was defined at 13.3 mg/m2 with DLT manifesting as grade 3 
thrombocytopenia and fatigue. A partial response was seen in a patient with renal cell 
carcinoma.223 Several patients with T-cell lymphoma (cutaneous or peripheral) exhibited 
significant reductions in skin lesions and tumor size after treatment with romidepsin.224, 
230  
A Phase II trial to define the response rate and toxicity profile in patients with T-
cell lymphoma was initiated due to the dramatic responses seen in Phase I trials.40 
Romidepsin was administered via a 4-h infusion on days 1, 8, and 15 of a 28-day cycle. 
Complete responses were observed in 4 patients (6%), and partial responses were 
observed in 20 patients (28%).231 The toxicities observed were consistent with those 
reported previously, including extreme fatigue, nausea and vomiting.223 
Granulocytopenia (failure of bone marrow to make white blood cells) and 
thrombocytopenia (low platelet counts) were observed as well, with values returning to 
baseline by the next cycle of treatment.231 
Defining a clear path for the development of romidepsin was somewhat 
complicated due to the many different parties involved. Fujisawa Corporation (now 
Astellas Inc.) discovered the compound in the early 1990s via a search for molecules that 
would revert the ras-driven oncogenic phenotype, and then, under a Cooperative 
Research and Development Agreement (CRADA), further oncology investigations were 
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initiated by the NCI in 1998. When the NCI confirmed that romidepsin was a powerful 
anticancer agent, Fujisawa Corporation initiated their own, separate clinical trials 
program in 2002. Romidepsin was licensed to Gloucester Pharmaceuticals in 2004; the 
company was later acquired by Celgene Corporation in 2010. Gloucester approached the 
U.S. FDA (beginning in 2004), obtained both Orphan Drug Status and Fast Track Status, 
and were able to come to an agreement, through the U.S. FDA Special Protocol 
Assessment (SPA) process, on a path to approval which was a pivotal single arm (Phase 
II) design, although data from the NCI’s ongoing study was also to be part of the New 
Drug Application (NDA) filing. Essentially, the activity of romidepsin, coupled with the 
unmet medical need in cutaneous T-cell lymphoma, were persuasive enough arguments 
to move the drug forward.  
 
Clinical Trials of Romidepsin  
Table 11 highlights the published clinical trial data on romidepsin; all of the 
Phase I trials were on patients who had non-responsive cancers. The favorable results of 
the NCI-sponsored multi-institutional Phase II trial,222, 228, 231, 232 followed by consistent 
results by the pivotal Phase II trial conducted by Gloucester Pharmaceuticals233 led to the 
approval by the U.S. FDA in November of 2009. 
 
Toxicity and Side Effects 
Cardiac toxicities were a primary concern in the early clinical trials due to 
preclinical results, leading to electrocardiograms (ECGs) and other measures related to 
 
87 
cardiac function being taken before and after every treatment.223 Many of the early 
toxicities were abnormalities of the ECG waveform, which represent repolarisation 
abnormalities in the electric functioning of the heart; grade 1 T-wave flattening or grade 2 
ST segment depression was observed in more than half of the ECGs, but although these 
abnormalities can also be indicative of cardiac ischemia, in the case of romidepsin this 
was not so, since they were not associated with elevation of cardiac troponin or with 
altered left ventricular function.232 Further follow up over 3 years with a larger body of 
clinical data confirms that the ECG abnormalities are not clinically significant or 
indicative of any real cardiac toxicity.210 Therefore, this observation is no longer a 
clinical concern, except that patients are screened with an ECG to check for pre-existing 
cardiac rhythm abnormalities, including the very rare congenital long QT syndrome, 
which is a condition where the interval between the Q-wave and the T-wave on the ECG 
is prolonged, and this can lead to further, even fatal, problems if the electrical circuitry of 
the heart is further affected in these patients.  
The majority of patients receiving romidepsin experience nausea, vomiting, and 
anorexia,223, 225, 229, 231, 234 and Grant et al.229 note that the antiemetic routine followed at 
the National Cancer Institute (NCI) was to administer 1 mg granisetron intravenously 
prior to romidepsin, followed by 1 mg orally every 12 h for 3 days.229 Progressive fatigue 
and occasional fever were also noted with romidepsin.223-225, 231, 234 
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Table 11. Clinical trials of romidepsin 
 
References 
223, 230 
222, 228, 231, 
232 
233 
224 
225 
226 
227 
236 
237 
238 
234 
239 
Outcome 
Dramatic response in two patients with 
T-cell lymphoma. 
34% response rate, complete response in 
4 patients. Cardiac pharmacokinetic, and 
pharmacodynamic data acquired. 
34% response rate, 6 patients with 
complete response. 
No demonstrated activity. 
Some clinical activity; more evident 
anti-leukemic activity in CLL patients. 
No objective responses. 
Limited clinical activity, though results 
indicated genetics may play a role in 
patient response to the drug. 
Limited antileukemic activity, 
possibility for combination therapy. 
No objective responses. 
Limited clinical activity, possibility for 
combination therapy. 
Limited clinical activity. 
Limited antitumor activity, possibility 
for combination therapy. 
Dose and Schedule 
17.8 mg/m2  
Day 1 and 5 of a 21-day cycle 
14mg/m2  
Day 1, 8, and 15 of a 28-day cycle 
14mg/m2  
Day 1, 8, and 15 of a 28-day cycle 
13.3 mg/m2  
Day 1, 8, and 15 of a 28-day cycle 
13 mg/m2  
Day 1, 8, and 15 of a 28-day cycle 
13 mg/m2  
Day 1, 8, and 15 of a 28-day cycle 
18 mg/m2  
Day 1 and 5 of a 21-day cycle 
13 mg/m2 
Day 1, 8, and 15 of a 28-day cycle 
13 mg/m2 
Day 1, 8, and 15 of a 28-day cycle 
17.8 mg/m2 
Day 1 and 7 of a 21-day cycle 
13 mg/m2 
Day 1, 8, and 15 of a 28-day cycle 
13 mg/m2 
Day 1, 8, and 15 of a 28-day cycle 
Number of 
Patients 
37 
98 
96 
33 
10 (CLL)  
10 (AML) 
18 
9 (AML)  
3 (MDS) 
20 
25 
19 
26 
35 
Target Disease 
Advanced or refractory 
neoplasms 
Cutaneous and Peripheral 
T-cell lymphoma 
Refractory cutaneous T-cell 
lymphoma 
Advanced cancers 
Chronic lymphocytic 
leukemia and acute myeloid 
leukemia 
Children with refractory or 
recurrent neoplasms 
Acute myelogenous 
leukemia and advanced 
myelodysplastic syndromes 
Acute myeloid leukemia 
Colorectal cancer 
Lung cancer 
Refractory metastatic renal 
cell cancer 
Metastatic castration-
resistant prostate cancer 
Phase 
I 
II 
II 
I 
I 
I 
I-II 
II 
II 
II 
II 
II 
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Also of concern are the hematological side effects; regular blood tests are 
administered to patients on romidepsin to monitor these symptoms.235 Leukopenia, 
granulocytopenia, and thrombocytopenia were all observed; in each case the effect is 
quickly reversed after cessation of the treatment.229, 231  
 
Synthetic Studies 
The main challenges in romidepsin’s synthesis include the asymmetric 
construction of the hydroxy mercapto heptenoic acid, the 16-membered cyclic 
depsipeptide ring itself (i.e. four amino acids and hydroxy mercapto heptenoic acid), and 
the intramolecular oxidative coupling of the thiols to produce the stable prodrug form of 
the molecule. The total synthesis was first completed in 1996 in 14 steps with an 18% 
overall yield.240 An improved synthesis utilizing 9 steps with a 13% overall yield was 
published in 2007,241 using, as in the first scheme, an asymmetric acetate aldol reaction 
and a lactonization step for macrolization. In 2008, Wen et al.242 utilized a lactamization 
as an alternative route to cyclization, reporting increased cyclization efficiency. However, 
due both to the chemical complexity of synthesis and the low yield of the producing 
organism, development was hindered mainly by shortages of the product.243 Therefore, 
attempts have been made to develop active analogs.  
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Figure 17. Structures of two romidepsin analogs (compounds 13 and 14), where the Z-
dehydrobutyrine (Z-Dhb) residue, which may be susceptible to a Michael addition, has been 
replaced with a valine moiety.244 
 
 
Using a series of synthetic analogs, Yurek-George et al.244 were able to examine 
the importance of several features of the romidepsin structure. They concluded that while 
the sulfur at position 13 does indeed function as a Zn-binding group within the HDAC 
active site, the cysteine residue is non-essential, provided that the Zn-binding thiol 
remains protected as in the oxidized pro-drug form.244 This assertion is supported by 
work done with linear compounds in which the thiol was masked as a thioester, 
undergoing enzymatic hydrolysis in the cell to produce the free thiol.245, 246 Yurek-George 
et al. also found that the unsaturated dehydrobutyrane residue could be replaced by less 
reactive side chains with no loss in in vitro potency, but that the macrocyclic scaffold 
itself was an essential component of HDAC inhibition.244 However, several small methyl 
ester structures without the macrocyclic backbone have proved to induce 
hyperacetylation in Drosophila S2 cells.247 These structures retain the disulfide link of 
romidepsin, thus preserving its prodrug quality. The analogs studied consisted of several 
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small cyclic disulfides; the number of methylene units in the ring was varied to provide a 
range of lengths for the linker from the ester to the reduced sulfhydryl group.247 Studies 
with HDAC inhibitors TSA and SAHA showed important interactions between the drugs 
and several phenylalanine residues surrounding the enzyme active site pocket,209 so the 
methyl ester was used to attach various lipophilic caps, in an effort to improve enzyme 
interaction.247 Despite these interesting medicinal chemistry studies, to the best of our 
knowledge, no analogs of romidepsin are in advanced stages of development. 
 
Conclusions 
As a potent HDAC inhibitor, romidepsin offers a promising new treatment for a 
disease with few existing therapies. It was approved by the U.S. FDA on November 5, 
2009 for use in patients with cutaneous T-cell lymphoma (CTLC), under the trade name 
Istodax®, marketed by Celgene Corporation (Summit, NJ). The dosing schedule was 
approved as 14 mg/m2 on days 1, 8 and 15 of a 28-day cycle.235 After a year of approval 
as an antineoplastic agent, preliminary information suggests that romidepsin is finding a 
real place in the treatment of CTCL, and the activity and manageable toxicity are helpful 
for both patients receiving treatment and doctors prescribing it (personal communication 
by several medical doctors to W.M.). At the time of preparation of this review, a 
supplemental new drug application (NDA) was being prepared for peripheral T-cell 
lymphoma (PTCL),248 and only time will tell if romidepsin’s use expands to the treatment 
of other cancers. 
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APPENDIX A 
SUPPLEMENTARY FIGURES AND TABLES 
 
Figure S1. UV spectra of compounds 1-6 as standards and in Juice D (two pages). 
Figure S2. Co-injections of analytes 3-6 and Juice D (two pages). 
Table S1. The mass of each capsule’s contents. AttentionLink was weighed in its entirety.  
Table S2.  Calculated content of bergamottin and DHB in supplements. These analytes were 
not detected in any of the other supplements tested.  
DHB = 6',7'-dihydroxybergamottin. 
Figure S3. UPLC-ELSD chromatograms of G142 in liquid media. The column was a BEH-
C18, and the gradient increased linearly from 15:85 CH3CN:H2O to 100:0 over 10 min. 
Abbreviations of media are defined in the Methods section. 
Table S3. NMR data (400 MHz, DMSO-d6) of compound 1. The experimental values were 
measured directly, as were the 1H NMR literature values (500 MHz, DMSO-d6). The 13C 
NMR values reported in the literature were derived through HMBC and HSQC experiments.  
Figure S4. Comparison of control (A) and dosed (B-D) growths of MSX 63935 grown in 
potato dextrose broth (left) and Czapek Dox broth (right). Cultures shown in (B) were grown 
with 50 µg/mL SAHA, (C) with 100 µg/mL 5-AZA, and (D) with 50 µg/mL bortezomib. The 
separation was performed via UPLC-PDA (235 nm), using a C18 column and a gradient 
increasing linearly from 10% CH3CN (H2O) at 0.0 min to 100% at 4.5 min, held at 100% for 
an additional 0.5 min.  
Figure S5. 1H NMR spectrum 9 [400 MHz, MeOH-d4]. 
Figure S6. 13C NMR spectrum of 9 [400 MHz, MeOH-d4]. 
Figure S7. 1H NMR spectrum of 10 [400 MHz, MeOH-d4]. 
Figure S8. 13C NMR spectrum of 10 [600 MHz, MeOH-d4]. 
Figure S9. UPLC-PDA (235 nm detection) chromatograms of compounds 1 (top) and 2 
(bottom) demonstrating purity. The purity of compound 1 is >99%, and the purity of 
compound 2 is >91%. The separation was performed using a C18 column and a gradient 
increasing linearly from 10% CH3CN (H2O) at 0.0 min to 100% at 4.5 min, held at 100% for 
an additional 0.5 min.  
 
101 
 
 
Figure S1. UV spectra of compounds 1-6 as standards and in Juice D. Continued on next 
page. 
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Figure S1 (continued). UV spectra of compounds 1-6 as standards and in Juice D. 
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Figure S2. Co-injections of analytes 3-6 and Juice D. Continued on next page. 
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Figure S2 (continued). Co-injections of analytes 3-6 and Juice D.  
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Table S1. The mass of each capsule’s contents. (AttentionLink was weighed in its 
entirety.) 
 
 
1 2 3 4 5 AVE RSD 
SciFit DHB 300 383.77 366.58 350.90 384.20 402.60 377.6 5.20 
Trisorbagen 350.69 345.86 353.62 313.65 358.61 344.5 5.18 
Xceler8 DHB 242.50 203.86 191.22 205.59 216.94 212.0 9.11 
AttentionLink 990.58 943.97 973.68 942.45 1011.71 972.5 3.08 
Finaflex Alpha 621.29 636.33 664.30 632.12 617.64 634.3 2.90 
Finaflex Andro 703.27 677.01 682.31 677.53 671.31 682.3 1.81 
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Table S2. Calculated content of bergamottin and DHB in supplements. These analytes 
were not detected in any of the other supplements tested. 
DHB = 6',7'-dihydroxybergamottin. 
  
 
μg/capsule SD % weight of capsule SD 
DHB in SciFit (PDA)         
LOQ 0.22 
   LOD 0.074 
     
    Capsule 1 (383.77 mg) 66.68 0.64 0.01738 0.00017 
Capsule 2 (366.58 mg) 57.83 0.64 0.01577 0.00017 
Capsule 3 (350.9 mg) 64.06 0.64 0.01826 0.00018 
Capsule 4 (384.2 mg) 68.29 0.64 0.01778 0.00017 
Capsule 5 (402.6 mg) 70.69 0.64 0.01756 0.00016 
     Bergamottin in SciFit (PDA)     
LOQ 2.0 
   LOD 0.12 
     
    Capsule 1 (383.77 mg) 11.70 0.23 0.003050 0.000061 
Capsule 2 (366.58 mg) 11.56 0.23 0.003152 0.000064 
Capsule 3 (350.9 mg) 11.86 0.23 0.003380 0.000066 
Capsule 4 (384.2 mg) 12.29 0.23 0.003200 0.000061 
Capsule 5 (402.6 mg) 13.24 0.23 0.003289 0.000058 
     Bergamottin in Xceler8 (MS)     
LOQ 0.18 
   LOD 0.060 
     
    Capsule 1 (242.5 mg) 2.977 0.069 0.001227 0.000029 
Capsule 2 (203.86 mg) 2.644 0.069 0.001382 0.000036 
Capsule 3 (191.22 mg) 2.582 0.069 0.001267 0.000034 
Capsule 4 (205.59 mg) 2.509 0.069 0.001220 0.000034 
Capsule 5 (216.94 mg) 2.816 0.069 0.001298 0.000032 
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Table S3. NMR data (400 MHz, DMSO-d6) of compound 1. The experimental values 
were measured directly, as were the 1H NMR literature values (500 MHz, DMSO-d6). 
The 13C NMR values reported in the literature were derived through HMBC and HSQC 
experiments.  
 Experimental Values  Literature Valuesa 
position δC δH, mult. (J in Hz)  δC δH, mult. (J in Hz) 
5' 13.9 0.86, t (7.1)  14.7 0.86, t (6.9) 
4' 18.2 1.41, 1.32, m  18.9 1.41, 1.32, m 
3' obscured (DMSO) 1.41, m  39.8 1.41, m 
1' 41.7 2.55, dd (8.7, 14.2) 2.70, dd (4.6, 14.2)  42.1 
2.55, dd (8.1, 14.5)  
2.66, dd (4.6, 14.3) 
O-Me 56.1 3.87, s  56.2 3.82, s 
2' 67.4 3.88, m  68.0 3.87, m 
6 100.6 6.84, d (2.3)  98.2 6.50, d (2.4) 
3 110.7 6.09, s  110.3 5.98, s 
4a 111.8   111.5  
8 113.1 7.07, d (2.3)  113.4 6.78, d (2.4) 
5 not observed   147.1  
8a 157.8   158.8  
7 162.7   163.5  
2 166.7   166.4  
COOH 169.2   172.6  
4 175.4   177.2  
aConrad, J., et al.; J. Nat. Prod. 2009, 72, 835-840. 
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Figure S3. UPLC-ELSD chromatograms of G142 in liquid media. The column was a BEH-
C18, and the gradient increased linearly from 15:85 CH3CN:H2O to 100:0 over 10 min. 
Abbreviations of media are defined in the Methods section. 
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Figure S4. Comparison of control (A) and dosed (B-D) growths of MSX 63935 grown in 
potato dextrose broth (left) and Czapek Dox broth (right). Cultures shown in (B) were 
grown with 50 µg/mL SAHA, (C) with 100 µg/mL 5-AZA, and (D) with 50 µg/mL 
bortezomib. The separation was performed via UPLC-PDA (235 nm), using a C18 column 
and a gradient increasing linearly from 10% CH3CN (H2O) at 0.0 min to 100% at 4.5 
min, held at 100% for an additional 0.5 min.  
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Figure S5. 1H NMR spectrum 9 [400 MHz, MeOH-d4]. 
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Figure S6. 13C NMR spectrum of 9 [400 MHz, MeOH-d4]. 
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Figure S7. 1H NMR spectrum of 10 [400 MHz, MeOH-d4]. 
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Figure S8. 13C NMR spectrum of 10 [600 MHz, MeOH-d4]. 
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Figure S9. UPLC-PDA (235 nm detection) chromatograms of compounds 1 (top) and 2 
(bottom) demonstrating purity. The purity of compound 1 is >99%, and the purity of 
compound 2 is >91%. The separation was performed using a C18 column and a gradient 
increasing linearly from 10% CH3CN (H2O) at 0.0 min to 100% at 4.5 min, held at 100% 
for an additional 0.5 min.  
 
